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Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder 
characterized by two main pathological features: neurofibrillary tangles (NFTs) 
composed of hyper-phosphorylated Tau protein and extracellular deposition of amyloid 
β peptide (Aβ) into plaques, found mainly in cortex and hippocampus. Brain levels of 
Aβ peptide, which is derived from proteolytic hydrolysis of amyloid-beta precursor 
protein (APP), are regulated by its production, its degradation and clearance through 
the brain, namely across the blood-brain barrier (BBB). Indeed, increasing evidence 
demonstrated that increased Aβ levels are a result of its faulty elimination across the 
BBB. Several molecules have been proposed as Aβ carriers and among them 
transthyretin (TTR) has been shown to be the major Aβ-binding protein in the 
cerebrospinal fluid (CSF), leading to decreased peptide aggregation and toxicity. 
Supporting the importance of TTR in AD is the observation of its decreased levels in 
CSF and plasma. It has been also suggested that TTR tetrameric stability is a key 
factor in TTR/Aβ interaction. Moreover, in vivo administration of iododiflunisal (IDIF), 
known to be a potent TTR tetrameric stabilizer, to an AD mice model resulted not only 
in decreased brain Aβ levels and deposition but also in improved cognitive function 
associated to the AD-like neuropathology in this AD model.  Aβ levels were reduced in 
plasma and presented a trend for reduction in the CSF, suggesting TTR promoted Aβ 
clearance from the brain and the periphery. Furthermore, TTR expression in neurons 
has been recently reported, as well as the co-localization of extracellular TTR with Aβ 
in plaques, although it is still very controversial. Taking all these data into account, we 
hypothesize that TTR might also be involved in Aβ clearance at BBB.  
This project aims at investigating the influence of TTR in Aβ transport across 
the BBB, using an in vitro BBB cellular model and an in vivo study, and also at 
investigating the mechanisms leading to neuronal TTR expression using a neuronal 
cell line.  
 In order to achieve our main goals, we started by evaluating the effect of TTR 
in Aβ plasma levels in AD/TTR transgenic mice with different ages and distinct 
genotypes for TTR. Our results showed that, Aβ1-42/Aβ1-40 ratios were elevated in 
plasma of AD/TTR+/- mice compared with AD/TTR+/+ animals, at the age of 6 months at 
which senile plaque formation starts, in this model. This indicates that TTR contributes 
to the maintenance of normal plasma Aβ levels, supporting the idea that TTR promotes 
its elimination from the brain and from the periphery.  
After setting up and optimizing our cellular model, the hCMEC/D3 cell line, we 
performed internalization studies of labelled (FAM-Aβ1-42) or non-labelled Aβ peptide 
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(Aβ1-42) in the presence and absence of TTR, using flow cytometry and fluorescence 
microscopy. Our FACS results showed less internalization in the presence of TTR 
while fluorescence microscopy assays revealed no significant TTR effect in Aβ uptake. 
Further tests performed, using short periods of incubation, showed however, that TTR 
promoted Aβ internalization and possibly its degradation, as assessed by a fluorometric 
analysis of cellular lysates and supernatants. These results also indicated that in the 
initial analysis by FACS and fluorescence microscopy, and because cells were 
incubated for 3 hours, Aβ was internalized and then flowed out of cells, explaining the 
lower levels. We also conducted permeability studies to assess the effect of TTR in Aβ 
efflux, using cell monolayers established in transwells filters and measured Aβ 
transport from the basolateral (brain) to the apical (blood) side. The results showed that 
only TTR added to the basolateral chamber is able to promote Aβ efflux, when 
comparing to TTR added to the apical side. The permeability of TTR across the cell 
monolayers was also evaluated, and our results demonstrated that TTR was capable to 
cross the hCMEC/D3 cell monolayer, mostly from brain-to-blood, which was lower in 
the presence of Aβ. We suggest that TTR, while transporting Aβ, also crosses the 
monolayer or that Aβ causes impaired BBB integrity. Additionally, we performed a 
preliminary in vivo study, using mice with two copies of TTR (TTR+/+), carrying only one 
copy of the TTR gene (TTR+/-) and animals without TTR (TTR-/-). We injected FAM-
Aβ1-42 intracranially and our results indicated that, 30 minutes post injection, brains 
from TTR+/- mice retained less peptide than TTR-/- animals, further supporting a TTR 
role in Aβ brain efflux, corroborating our in vitro permeability results. However, we 
could not conclude on FAM-Aβ1-42 brain levels in TTR+/+ mice, due to technical issues. 
To further understand which mechanisms or stimulus  are behind the induction 
of TTR gene expression in neurons, we decided to investigate if high levels of soluble, 
oligomeric and fibrillar forms of Aβ could induce such expression in a SH-SY5Y 
neuroblastoma cell line. We also studied the expression pattern of APP isoforms. Real-
time polymerase chain reaction (RT-PCR) analysis showed that oligomers and fibrils 
were capable to induce TTR expression and to increase the expression of APP 
isoforms (i.e. total APP), whereas soluble Aβ did not cause a significant effect. We 
assessed also if 695APPswe gene produce TTR expression using the same cell line 
and our results showed no TTR expression. Finally, we evaluated if exogenous TTR 
could induce an alteration in APP isoforms expression, and no differences were 
observed in cells in presence or absence of TTR. 
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In summary, our results strengthen the importance of TTR in AD, indicating this 
protein as a promoter of Aβ clearance across the BBB. Our research also provided 
evidence that neuronal TTR production is a reaction to toxic Aβ species, further 
supporting TTR as a protective protein in the central nervous system (CNS). 
 
Keywords: Alzheimer’s disease, Amyloid β peptide, Blood-brain barrier, Transthyretin. 
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A doença de Alzheimer (DA) é uma patologia neurodegenerativa debilitante 
caracterizada particularmente por duas lesões: emaranhados neurofibrilares, 
compostos por proteína tau híper-fosforilada, e a deposição extracelular do péptido β 
amiloide (βA) em placas senis ou neuríticas, encontradas principalmente no córtex e 
hipocampo. O péptido βA resulta da hidrólise proteolítica da proteína precursora 
amiloide (PPA) e os seus níveis no cérebro são regulados pela sua produção, 
degradação e eliminação através do cérebro, nomeadamente através da barreira 
hemato-encefálica (BHE). E, de facto, tem sido mostrado que os níveis de βA estão 
aumentados devido a uma eliminação ineficiente através da BHE. No mesmo contexto, 
e nos últimos anos, várias moléculas têm sido sugeridas como transportadoras do 
péptido βA, e entre elas, a transtirretina (TTR) tem sido descrita como a principal 
proteína transportadora do βA no líquido cefalorraquidiano (LCR), provocando uma 
diminuição da sua agregação, e consequentemente da sua toxicidade. A importância 
da TTR na DA é sustentada também pelo facto dos seus níveis estarem reduzidos no 
LCR e no plasma, e ainda a evidência de que a estabilização da sua estrutura é um 
fator crítico para a interação TTR/βA. Além disso, a administração in vivo do composto 
iododiflunisal (IDIF), conhecido por ser um potente estabilizador do tetrâmero da TTR, 
a um modelo animal de DA resultou não só num decréscimo dos níveis de βA, e na 
sua deposição no cérebro dos murganhos, como também na melhoria das funções 
cognitivas habitualmente afetadas nesta patologia. Foi ainda demonstrado que os 
níveis do péptido βA estavam reduzidos no plasma e apresentavam também uma 
tendência para redução no LCR, sugerindo que a TTR promove a eliminação do 
péptido βA do cérebro para a periferia. Além destas evidências, tem sido recentemente 
demonstrada a expressão da TTR em neurónios, como também a sua co-localização 
extracelular com o Aβ em placas, embora esta seja ainda uma discussão muito 
controversa. Tendo isto em conta, formulamos a hipótese de que a TTR poderá estar 
envolvida na eliminação do péptido βA através da BHE.  
Este projeto tem como objetivo investigar a influência da TTR no transporte do 
βA através da BHE, utilizando um modelo celular da BHE e um estudo in vivo, e ainda 
procurar mecanismos que levem à expressão da TTR neuronal, usando um modelo 
celular neuronal. 
Para alcançarmos os nossos objetivos, começamos por avaliar o efeito da TTR 
nos níveis de βA no plasma de murganhos transgénicos DA/TTR com diferentes 
idades e genótipos para a TTR. Os nossos resultados demonstraram que, o rácio βA1-
42/βA1-40 apresentou-se mais elevado nos plasmas dos murganhos DA/TTR+/- em 
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comparação com os animais DA/TTR+/+, aos seis meses de idade, altura descrita 
como o início da deposição cerebral do péptido βA neste modelo. Isto indica que a 
TTR contribui para a manutenção dos níveis fisiológicos de βA no plasma, sustentando 
a ideia que a TTR promove a sua eliminação do cérebro para a periferia. 
Após otimização do nosso modelo celular, a linha celular hCMEC/D3, foram 
realizados estudos de internalização do péptido βA fluorescente e não fluorescente na 
presença ou ausência da TTR, utilizando citometria de fluxo e microscopia de 
fluorescência. Os resultados de citometria de fluxo mostraram diminuição da 
internalização do βA na presença da TTR, enquanto a microscopia de fluorescência 
não revelou diferenças significativas no efeito da TTR na internalização do βA. A 
análise fluorométrica dos lisados celulares e sobrenadantes com tempos de incubação 
mais curtos, demonstrou, no entanto, que a TTR promove a internalização do βA e que 
possibilita a sua degradação. Estes resultados também parecem indicar que, na 
análise inicial por citometria e microscopia de fluorescência, e porque as células foram 
incubadas durante 3 horas, o βA foi internalizado e, em seguida, começou a ser 
transportado para o exterior das células, explicando-se assim, os seus níveis mais 
baixos. Realizaram-se também estudos de permeabilidade para avaliar o efeito da 
TTR no efluxo do βA, usando monocamadas de células em filtros de Transwells, onde 
o transporte do βA foi medido a partir do transporte basolateral (cérebro) para o lado 
apical (sangue). Os resultados mostraram que apenas a TTR adicionada no lado 
basolateral é capaz de promover o efluxo do βA, comparando com a situação em que 
a TTR é adicionada ao lado apical. A permeabilidade da TTR através das 
monocamadas de células foi também avaliada, e os nossos resultados demonstraram 
que a TTR foi capaz de atravessar a monocamada celular, sendo mais evidente o 
transporte do cérebro para o sangue, mas menos acentuado na presença de βA. 
Sugerimos, por isso, que a TTR enquanto transporta o βA pode também atravessar a 
monocamada, ou então que o βA pode causar danos na BHE, afetando a sua 
integridade. Para além disso, foi efetuado um estudo preliminar in vivo, utilizando 
murganhos com duas cópias de TTR (TTR+/+), com uma cópia de TTR (TTR+/-) e sem 
TTR (TTR-/-). Um Péptido βA fluorescente foi injetado intracranialmente e os resultados 
indicaram que, 30 minutos após a injeção, os cérebros dos murganhos TTR+/- 
apresentavam menos βA que os animais TTR-/-, apoiando ainda mais o papel da TTR 
no efluxo do βA através do cérebro, corroborando os nossos resultados de 
permeabilidade in vitro. No entanto, não foi possível concluir sobre os níveis cerebrais 
de βA em murganhos TTR+/+, devido a problemas inerentes à metodologia utilizada. 
FCUP/ICBAS 
Resumo 
19 
 
Para entender melhor os mecanismos ou estímulos que estão envolvidos na 
indução da expressão do gene da TTR em neurónios, decidimos investigar se 
elevados níveis de βA solúvel, oligomérico e fibrilar poderiam induzir tal expressão 
numa linha de celular neuroblastoma SH-SY5Y. Estudamos também a expressão do 
padrão de isoformas de PPA. A análise por reacção em cadeia da polimerase em 
tempo real (RCP-TR) mostrou que oligómeros e fibras foram capazes de induzir a 
expressão de TTR e de aumentar a expressão das isoformas de PPA (ou seja, o PPA 
total), ao passo que o βA solúvel não causou nenhum efeito significativo. Também 
avaliamos se o gene 695APPswe induzia a expressão de TTR utilizando a mesma 
linha celular, e os nossos resultados não mostraram expressão de TTR. Finalmente, 
avaliámos se a TTR exógena poderia induzir uma alteração na expressão das 
isoformas de PPA, mas não foram observadas diferenças nas células em presença ou 
ausência de TTR.  
Em suma, os nossos resultados reforçam a importância da TTR na DA, 
indicando que esta proteína pode funcionar como um promotor do efluxo do βA 
através da BHE. O nosso estudo também forneceu evidências de que a produção de 
TTR neuronal é uma reação às espécies tóxicas de βA, apoiando ainda mais a TTR 
como uma proteína protetora no sistema nervoso central (SNC). 
 
Palavras-chave: Doença de Alzheimer, Péptido β amiloide, Barreira hemato-
encefálica, Transtirretina. 
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BCSFB - Blood-cerebrospinal fluid barrier 
bFGF - Basic fibroblast growth factor  
BSA - Bovine serum albumin  
CNS - Central nervous system  
CO2 - Carbon dioxide 
CTF - C-terminal fragment  
CuBD - Copper-binding domain  
DCPA - 2-((3,5Dichlorophenyl) amino) benzoic acid 
DFPB - 4-(3,5-difluorophenyl)  
DMP - Dimethyl pimelimidate  
DNP- Dinitrophenol  
EBM-2 medium - Endothelial Cell Growth Medium 
ECs - Endothelial cells 
EMEM - Eagle’s minimum essential medium  
EOAD - Early-onset AD 
FAC - Familial amyloidotic cardiomyopathies 
FAP - Familial amyloidotic polyneuropathy 
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FBS - Fetal bovine serum  
FITC - Fluorescein isothiocyanate  
FMRI - Functional magnetic resonance imaging  
GDNF - Glial-derived neurotrophic factor  
GSK3β - Glycogen synthase kinase 3β  
GWAS - Genome-wide association studies  
hCMEC/D3 cell line - Immortalized human cerebral microvascular endothelial cell line  
HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HPBD1 - Heparin-binding/growth-factor-like domain 1  
HPBD2 - Heparin-binding/growth-factor-like domain 2  
hrec TTR - Human recombinant TTR  
HSF1 - Heat shock factor 1  
ICV - Intracerebroventricularly  
IDIF – Iododiflunisal 
IGF - Insulin-like growth factors  
IP - Intraperitoneal injection 
ISF - Interstitial fluid  
JAMs - Junctional adhesion molecules  
KPI - Kunitz-type protease inhibitor domain  
LOAD - Late-onset AD 
LRP1 - Low-density lipoprotein receptor-related protein 1  
MCI - Mild cognitive impairment 
MRI - Magnetic resonance imaging  
NEAA - Non-essential amino-acids  
NFT - Neurofribrillary tangles  
PBS - Phosphate-buffered saline  
PBS-T - Phosphate-buffered saline containing 0.05% Tween-20  
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PEN2 - Presenilin enhancer 2  
PET - Positron emission tomography   
PFA - Paraformaldehyde 
PHFs - Paired helical filaments 
PMSF - Phenylmethylsulphonyl fluoride  
PNS - Peripheral nervous system  
PP - Protein phosphatase  
PSEN1 - Presenilin 1 
PSEN2 - Presenilin 2 
p-tau - Phosphorylated tau  
RAGE - Receptor for advanced glycation end products 
RBP - Retinol binding protein  
RC - Random coil region 
RMT - Specific receptor mediated transcytosis  
rpm - Rotations per minute  
RT - Room temperature  
RT-PCR - Real-time Polymerase Chain Reaction  
sAPP - Soluble secreted form of APP  
SORL1 - Sortilin-related receptor  
SP - Signal peptide 
SPECT - Single photon emission computed tomography 
SSA - Systemic amyloidosis  
T4 - Thyroid hormone thyroxine 
TBS - Tris-buffered-saline 
TEER - Transendothelial electrical resistance  
TGF-β - Transforming growth factor beta 
TJ - Tight junctions 
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t-tau - Total tau  
TTR - Transthyretin 
VEGF - Vascular endothelial growth factor  
ZnBD - Zinc-binding domain 
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Dementia is one of the major concerns for society and is independent of social, 
economic, ethnic or geographical boundaries. Currently more than 44.4 million people 
are affected worldwide and the number of affected people is estimated to 75.6 million in 
2030, and 135.5 million in 2050 (International; 2014). Epidemiologic research of 
dementia in Portugal revealed that approximately 153.000 people suffer from dementia 
(Portugal, 2009). 
This mental disorder is caused by a damage of neurons in several brain 
regions, leading to a loss of cognitive brain functions and memory impairment (Grimm 
et al. , 2013). These, in turn, can lead to a decline in memory, thinking, reasoning, 
verbal communication, behavior and emotion, interfering with independence in 
everyday activities. Different types of dementia have been described, among them are: 
vascular dementia, dementia with Lewy bodies, Parkinson’s disease dementia, 
Creutzfeldt-Jakob disease, mixed dementia, Fronto-temporal dementia and Alzheimer’s 
disease (AD) (Fargo et al. , 2014).  
In the next topics will be exposed several aspects related to the most common 
type of dementia, AD, and will be debated the role of transthyretin (TTR) in this 
disorder, as well as, the clearance of amyloid-beta peptide (Aβ) through the Blood-
Brain Barrier (BBB). 
1. Overview of Alzheimer’s disease 
1.1. Alois Alzheimer and Alzheimer’s disease  
The first description of the clinical and histological findings of the “presenile 
dementia” was made by Alois Alzheimer (Figure 1A), a German psychiatrist and 
neurophatologist, in 1907 (Alzheimer et al. , 1995). His famous paper entitled “Über 
eine eigenartige Erkranlkung der Hirnrinde” described a 51-year old woman patient, 
Auguste Deter (Figure 1B), who had developed progressive memory impairment, 
paranoid ideas, delusions, hallucinations and disorientation in time and space 
(Alzheimer et al. , 1995; Small et al. , 2006; Jellinger, 2006). Later, when she died, 
Alzheimer detected, in her atrophic brain, degenerating neurons with bundles of fibrils 
(neurofibrillary tangles), using a developed Bielschowsky’s silver staining method, and 
miliary deposits (senile plaques) all over the cortex (Alzheimer et al. , 1995; Jellinger, 
2006). However, Alois Alzheimer was not the first to describe these unusual senile 
aggregates. In the same year, Fischer had already published a paper where first 
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described senile plaques (Figure 1C) in 12 cases of senile dementia (Goedert, 2009). 
The “presenile dementia” was renamed into Alzheimer’s disease, in 1910 by Emil 
Kraepelin (Alzheimer’s mentor) and, in the same year, she included this disorder in the 
Textbook of Psychiatry (Jellinger, 2006; Verhey, 2009). 
 
After the preliminary work of Alzheimer, several scientists proceeded his clinical 
studies, in order to acquire the necessary knowledge to unravel the mystery around 
this devastating disease, currently known as the disease of the 21th century (Jellinger, 
2006).   
Presently, AD is considered a progressive neurodegenerative disorder of the 
central nervous system (CNS) with increasing prevalence in the older population, over 
the age 65 (Qiu et al. , 2009; Grimm et al. , 2013). The prevalence and incidence of AD 
increase with age comprising approximately 70% cases of dementia worldwide, with 
notable incidence in North America and Western Europe (Reitz et al. , 2011). In 
Portugal, this disease affects more than 90.000 people and  this means that, about 1% 
of the total Portuguese population suffers from this condition (Portugal, 2009). 
Clinically, AD is characterized by a progressive decline in cognitive functions, 
such as memory, language, perception, reasoning and learning, ultimately leading to 
death (Alzheimer et al. , 1995; Fargo et al. , 2014). According to the new diagnostic 
criteria and guidelines, revised in 2011 by the National Institute of Aging and the 
Alzheimer Association, there are three different stages of AD: preclinical AD, mild 
cognitive impairment (MCI) due to AD and dementia due to AD (Fargo et al. , 2014). 
Figure 1 – History of Alzheimer’s disease. Alois Alzheimer 1864-1915 (A), its first patient, Auguste Deter, (B) and 
drawings of senile plaques from the illustrations of Fischer’s paper (C). Adapted from: A - Verhey, 2009; B - Jellinger, 
2006; C - Goedert, 2009 
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These pre-established stages aim at helping the medical entities in the diagnosis of 
patients presenting dementia symptoms and, thus, defining the development of the 
disease so that the proper monitoring is provided.  
1.2. Genetics of Alzheimer’s Disease 
AD is classified into two forms based on its age of onset: Early-onset AD 
(EOAD), which typically develops before the age 65, accounting for 1-5% of all cases, 
and the late-onset AD (LOAD), which normally occurs late in life (>65 years) and 
affects more than 95% of Alzheimer’s patients  (Blennow et al. , 2006; Piaceri et al. , 
2013; Reitz et al. , 2014).  
Early onset form is associated with a Mendelian pattern of inheritance and it is 
an autosomal, dominant and familial form of disease (Blennow et al. , 2006). However, 
the majority of the patients with EOAD are sporadic cases, without family history of the 
disease (Piaceri et al. , 2013). Three different genes are involved in the 
pathophysiology of EOAD: Amyloid β Precursor Protein (APP) gene, presenilin 1 
(PSEN1) and presenilin 2 (PSEN2) genes. Mutations in any of these three genes, 
which all encode proteins linked to APP, interfere with Aβ production and processing 
(Tanzi, 2012; Reitz et al. , 2014).  
In contrast, LOAD onset form is sporadic and a heterogeneous form of the 
disease and the main risk factor is aging. Several genetics studies demonstrated that 
LOAD has a substantial genetic contribution (~60-80%) and is extremely influenced by 
environmental factors (Gatz et al. , 2006; Piaceri et al. , 2013). Thus, genetic risk 
factors are extremely studied, being the apolipoprotein E (APOE) one of the most 
investigated gene.  
The relationship between APOE gene and LOAD is described since 1993 
(Saunders et al. , 1993) and, lately associated as the major susceptibility gene for 
sporadic AD (Coon et al. , 2007). The APOE gene encodes a 299-aminoacid 
lipoprotein responsible for maintaining the cholesterol homeostasis, and this protein 
exists as three different isoforms: ɛ2, ɛ3 and ɛ4 (Piaceri et al. , 2013). Carriers of the 
APOE ɛ4 allele, located on chromosome 19q13, are more susceptible to development 
AD when compared with noncarriers, however this allele is not sufficient by itself to 
generate this disorder (Corder et al. , 1993., Schmidt et al. , 2014).  
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Sortilin-related receptor gene (SORL1), which is located on chromosome 11, is 
another gene genetically associated to LOAD, and encodes a neuronal receptor for 
ApoE (Rogaeva et al. , 2007; Reitz et al. , 2011).  Andersen and his colleagues 
verified, in a study involving mice and human AD samples, that under-expression of 
SORL1 leads to the over-expression of Aβ, and also that SorL1 receptor is involved in 
the APP processing and trafficking (Andersen et al. , 2005).  
In addition, other genes associated with LOAD, were identified by the Genome-
wide association studies (GWAS): CLU (clusterin or apolipoprotein J), PICALM 
(phosphatidylinositol binding clathrin assembly protein), CR1 (complement component 
C3b/C4b), BIN1 (amphiphysin II), ABCA7, MS4A cluster (MS4A6A/ MS4A4E), CD2AP, 
CD33 and EPHA1 (Harold et al. , 2009, Hollingworth et al. , 2011a, Hollingworth et al. , 
2011b, Lambert et al. , 2009, Seshadri et al. , 2010, Naj et al. , 2011). In summary, 
these genes are involved in several pathways related with APP and Aβ processing, Aβ 
production and lipid metabolism and endocytosis (Reitz et al. , 2014). Nevertheless, the 
mechanism by which these genes are involved in the pathogenesis of AD is still 
unclear.  
1.3. Non-genetic risk factors for Alzheimer’s Disease 
The vast majority of AD cases are not directly related to genetic factors. A group 
of factors between the environment and the lifestyle of people seems to have a 
significant role in AD (Alves et al. , 2012). 
Age is the greatest risk factor for this incurable disease, but advanced age is 
not sufficient to trigger by itself the disease (Fargo et al. , 2014). In addition to age, a 
variety of others factors are involved with AD include a family history of the disorder, 
hypertension, hypercholesterolemia, diabetes, Down’s syndrome, cardiovascular 
disease, cerebrovascular disease, gender, education, smoking, high alcohol 
consumption and body weight (Masters et al. , 1985; Hebert et al. , 2001; Arvanitakis et 
al. , 2004; Reitz et al. , 2014).   
1.4. Histopathology of Alzheimer’s Disease 
This debilitating disorder is defined, pathologically, by the presence of 
extracellular amyloid-β plaques (senile plaques) and intracellular neurofibrillary tangles 
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(NFTs), which can lead to gliosis, neuronal and synaptic losses (Wenk, 2003; Paula 
VJR et al. , 2009; Pimplikar, 2009). 
 
1.4.1. Senile Plaques 
Neuritic or senile plaques are extracellular amyloid deposits found in the brain, 
mostly constituted by Aβ peptide. This distinctive lesion occurs in the CNS, more 
specifically in the hippocampus and the cortex (Costa et al. , 2008a). The amyloid 
plaques can be distinguished in different plaques subtypes, including neuritic, diffuse, 
primitive, compact, cored and cotton-wool. However, neuritic and diffuse plaques 
(Figure 2) are considered the most pathogenically significant subtypes in AD. In 
addition to the central core of Aβ peptide, neuritic plaques  (also designated classical or 
compact plaques) are surrounded by abnormal and dystrophic neurites (axons and 
dendrites), and activated microglia and reactive astrocytes. Moreover, diffuse plaques 
are more heterogeneous than senile plaques and, can evolve to compact plaques with 
increasing neuritic involvement (Castellani et al. , 2010).  
The classical amyloid plaques are not related only with AD, and are also 
associated with other diseases such as diffuse Lewy body, Down syndrome, dementia 
pugilistica and acute traumatic brain injury (Castellani et al. , 2010). 
 
 
 
 
 
 
 
 
1.4.2. Neurofibrillary Tangles (NFTs)  
The other molecular lesion associated to AD is intracellular NFTs (Figure 3), 
which are bundles of numerous paired helical filaments (PHFs) composed by two 
Figure 2 – Diffuse (A) and neuritic (B) plaques. Castellani et al. , 2010 
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axially opposed helical filaments with a diameter of 10 nm (Pevalova et al. , 2006; Perl, 
2010). These proteinaceous aggregates are formed by hyper-phosphorylated protein, 
tau, responsible for the assembly and stability of microtubules in the neuronal cell and 
for axonal transport (Mudher et al. , 2002; Perl, 2010). In addition to tau, several protein 
constituents are associated to this pathology, including ubiquitin, Aβ peptide and 
cholinesterases, although this microtubule-associated protein is considered the critical 
component of these filaments. Furthermore, NFTs are mainly present in the layer II 
neurons of the entorhinal cortex, in the CA1 and subicular regions of the hippocampus, 
and in the amygdala and the deeper layers (layers III, V and superficial VI) of the 
neocortex (Perl, 2010). 
These histopathological hallmark is not restricted to AD but also of other 
neurodegenerative diseases, such as Parkinson’s disease, Parkinsonian dementia, 
Pick’s disease, Down’s syndrome, progressive supranuclear palsy, Amyotrophic lateral 
sclerosis and dementia pugilistica (Gong et al. , 2005; Castellani et al. , 2010; Perl, 
2010). 
 
 
 
 
 
 
 
 
1.5. The role of Amyloid β Precursor Protein (APP) and Aβ formation 
As described previously, senile plaques are formed by deposition and 
aggregation of Aβ peptide, which is synthesized from a larger precursor protein called 
APP (Kim et al. , 2014). APP is a ubiquitously type I integral transmembrane protein 
and contains an extracellular N-terminal domain, a large ectodomain, one single 
transmembrane domain and a short intracellular C-terminal domain (Maltsev et al. , 
Figure 3 – Neurofibrillary tangles (A) and hyper-phosphorylated tau 
protein (B). Castellani et al. , 2010 
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2011; Grimm et al. , 2013). Currently, 32 APP autosomal dominant mutations have 
been identified and in most cases resulting in EOAD (Cruts et al. , 2012). 
The human APP gene is located on chromosome 21 and contains 18 exons 
spanning more than 170 kbp. The gene comprises several domains (Figure 4), 
including the region which encodes the Aβ sequence (part of exons 16 and 17), a 
signal peptide (SP), a heparin-binding/growth-factor-like domain 1 (HPBD1), a copper-
binding domain (CuBD), a zinc-binding domain (ZnBD), a Kunitz-type protease inhibitor 
domain (KPI), a second heparin-binding domain 2 (HPBD2), a random coil region (RC) 
(Yoshikai et al. , 1990; Zhou et al. , 2011). Three different isoforms of APP are derived 
from the alternative splicing of exons 7 and 8, and generates APP mRNAS for APP770, 
APP751 and APP695 (referring to a length in amino-acids), the last one being the 
major neuronal isoform. These isoforms differ principally by the absence (APP695) or 
presence (APP770, APP751) of a KPI domain (Zhou et al. , 2011).  
 
 
 
 
 
 
 
 
This transmembrane protein is one of the most abundant proteins in the CNS 
and it is also present in peripheral tissues, including epithelium and blood cells (Paula 
VJR et al. , 2009). The proteolytic processing of APP occurs by two distinct pathways: 
amyloidogenic pathway, that produces Aβ peptide, and non-amyloidogenic pathway 
that generates a secreted form of APP, sAPPα (Mudher et al. , 2002). 
The amyloidogenic processing pathway (Figure 5) combines the sequential 
actions of two enzymes: β- and γ-secretases (Kim et al. , 2014). The β-secretase, 
named β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1), cleaves APP 
and generates N-terminal soluble secreted form of APP, sAPPβ, and a C-terminal 
Figure 4 – Schematic representation of human APP gene. The gene is composed by a short 
intracellular tail, and a single transmembrane domain. Furthermore, the extracellular domain comprises 
SP, HBD1, CuBD, ZnBD, KPI, HBD2, RC and Aβ domains. Zhou et al. , 2011 
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fragment (CTF) called 99, which contains the Aβ sequence. The fragment CTF99 is 
subsequently cleaved by γ-secretase, generating the APP intracellular domain (AICD) 
and the amyloidogenic Aβ peptide (Maltsev et al. , 2011; Grimm et al. , 2013; Yan et al. 
, 2014).  
In the case of the non-amyloidogenic pathway (Figure 5), the APP is cleaved by 
the action of the enzyme α-secretase and is generated a soluble secreted amyloid 
precursor protein-α (sAPPα) and a carboxyl-terminal fragment (CTF83). Next, the 
CTF83 is digested by γ-secretase, liberating a non-amyloidogenic peptide (p3) and an 
AICD fragment (Muller et al. , 2012). 
The γ-secretase is a complex comprising at least four distinct proteins: PSEN1 
or PSEN2 as catalytic core, nicastrin, Aph (anterior pharynx defective) 1a or b, and 
presenilin enhancer 2 (PEN2) (Pasternak et al. , 2003). PSEN1 is the major constituent 
of this complex, and more than 180 mutations are known, which are the main causes of 
EOAD. Regarding the PSEN2 gene, currently 13 missense mutations causing EOAD 
were identified (Cruts et al. , 2012).  
 
Figure 5 – Schematic representation of APP processing. The figure shows that APP protein can be 
processed by two different pathways: amyloidogenic (black arrow) and non-amyloidogenic pathways (white 
arrow).  The APP is first cleaved by β- and α- secretases and generates sAPPβ/CTF99, and sAPPα/CTF83 
(amyloidogenic and non-amyloidogenic pathways respectively). Then, in the amyloidogenic processing, the 
CTF99 is cleaved by action of γ-secretase, liberating Aβ peptide and AICD fragments. Regarding the non-
amyloidogenic pathway, the CTF83 is digested by the same enzyme, γ-secretase, and resulting extracellular 
p3 and AICD fragments. Adapted from Kim et al. , 2014. 
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1.6. Aβ peptide as the cause of AD: the amyloid hypothesis 
1.6.1. Aβ peptide  
As described previously, Aβ peptide is derived from a sequential cleavage of 
APP, and was first isolated and sequenced by Glenner and Wong in 1984 (Glenner et 
al. , 1984). This peptide can be produced by several cells and found in plasma and 
cerebrospinal fluid (CSF).  
Aβ is a 4 kDa peptide with a β-pleated sheet configuration and its length can 
vary at the c-terminus, according the site where γ-secretase cleaves APP, generating 
peptides with different lengths between 39 and 43 amino-acids (Castellani et al. , 
2010). The 40 and 42 amino-acids species, Aβ1-40 and Aβ1-42 peptides respectively, 
are the most abundant isoforms in the brain, although the Aβ1-40 levels are higher 
than Aβ1-42 (Perl, 2010). The Aβ species (Figure 6) are released as monomers and 
then start to polymerizes into various structurally different forms, such as dimers, 
trimers, oligomers, protofibrils and fibrils, to finally deposit and aggregate into diffuse 
and, then neuritic plaques (Paula VJR et al. , 2009). Owing to its hydrophobic 
properties, the Aβ1-42 peptide is more prone to aggregation and fibrilization, being the 
most amyloidogenic specie (Perl, 2010). 
 
 
 
  
 
 
 
 
1.6.2. Amyloid cascade hypothesis 
Currently, several hypotheses are described trying to unmask the cascade that 
triggers Alzheimer’s disease. However, all the theories have fails and are not totally 
reliable.  
Figure 6 – Representation of distinct species of Aβ. Adapted from Hefti et al. , 2013 
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One of the theories is “Amyloid cascade hypothesis”. This was first described in 
the early 1990s, and postulates that the extreme deposition of Aβ peptide, as insoluble 
fibrillar form, into neuritic or senile plaques, due either to their increased production or 
decreased clearance, is the initiating event of this pathology (Hardy et al. , 1992). The 
accumulation of Aβ triggers a cascade of neurotoxic events, including mitochondrial 
dysfunction, increased oxidative stress, hyper-phosphorylated tau and subsequently 
NFTs formation (Morley et al. , 2014). Ultimately, this group of events leads to 
disruption of calcium homeostasis and synaptic and neuronal loss in critical brain areas 
related with cognitive functions (Paula VJR et al. , 2009; Alves et al. , 2012). 
Nevertheless, the original idea that amyloid plaques are pathogenic and the main 
cause of AD is quite controversial. Several studies revealed, by the post-mortem 
observation of AD patient’s brains with severely impaired memory, absence of amyloid 
plaques, and another study with mouse model of AD shows that animals 
with amyloid plaques have normal memory function (Lesne et al. , 2008; Pimplikar, 
2009). 
Accumulating scientific data suggest that soluble Aβ oligomers represent the 
most toxic form of this protein that can cause AD. Three specific forms of Aβ oligomers, 
isolated from brains of AD patients or from transgenic mouse models of AD, were 
identified: Aβ dimers (≈ 8 kDa), Aβ trimers (≈ 12 kDa) and Aβ*56 (≈ 56 kDa) (Lesne et 
al. , 2006; Shankar et al. , 2008). Regarding this, Lesne et al. suggested that 
accumulation of Aβ*56 oligomers in the brain, causes memory deficits in a middle-aged 
Tg2576 mice (Lesne et al. , 2006), and another recent study, demonstrated that, 
injection of Aβ*56 oligomers intracerebroventricularly (icv) in transgenic mice brains, 
impairs brain function and affects mice cognitive functions (Reed et al. , 2011). In 
contrast, Aβ trimers effect is less clear, but Aβ dimers seem to have a synaptotoxic 
effect (Shankar et al. , 2008; Reed et al. , 2011).  
Despite all the advances, several investigators have increasingly questioned the 
validity of amyloid hypothesis and if Aβ is or not the cause of AD. Thus, many 
hypotheses to explain AD pathogenesis are ongoing, including pathways that do not 
link to amyloid, such as the “tau and tangles hypothesis”. 
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1.7. Tau and tangles hypothesis 
In mid 1980s, a study revealed that tau protein is the main constituent of NFTs, 
one of the hallmarks of AD (Wood et al. , 
1986). The tau protein is abundant in neurons 
of the CNS, but is also expressed in CNS 
astrocytes and oligodendrocytes, and further 
existent in peripheral nervous system (PNS) 
(Paula VJR et al. , 2009; Kim et al. , 2014). 
This protein is responsible for stabilizing the 
microtubules, and belongs to the microtubule-
associated proteins (MAP). A total of six 
different human isoforms of tau derived from 
a single gene (MAPT gene), located on 
chromosome 17 where it occupies over 100 
kb and contains 16 exons, via splicing 
alternative (Avila et al. , 2004).  
Structurally, tau protein comprises two 
different domains: the projection domain that 
contains the amino-terminal and the 
microtubule binding-domain containing the 
carboxyl-terminal. The projection domain is 
composed by the N-terminal rich in acidic 
residues and the proline-rich region, and the 
microtubule-biding domain has the tubulin-
biding and acidic C-terminal regions (Avila et 
al. , 2004). 
Under physiological conditions, tau 
binds to tubulin in order to promote the 
polymerization and inhibit the fast 
depolymerization of the tubulin. This process 
occurs by regulation of phosphorylation state 
of tau, and tau can be phosphorylated in 79 
phosphorylation sites at serine and threonine 
residues. Consequently, the balance between 
Figure 7 – Representation of NFTs formation. 
Hyper-phosphorylated Tau contributes to a 
destabilized microtubule network and NFTs formation, 
leading to neuronal death. Martin et al. , 2011 
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phosphorylation and dephosphorylation is crucial in order to promote the assembly and 
stabilization of the microtubules of the neurons. The most important enzyme, 
responsible for tau phosphorylation, is the enzyme glycogen synthase kinase 3β 
(GSK3β), but also another kinases and phosphatases, such as protein phosphatase 
(PP) 1 (PP1), PP2A and PP2B, are involved in this process (Paula VJR et al. , 2009).  
On the other hand, in AD, tau is abnormally hyper-phosphorylated and this 
leads to the loss of its biological function, causing a decrease in the tau interaction with 
microtubules. This promotes the increase of soluble tau in the monomeric form 
enabling its aggregation into dimers and oligomers/protomers and then into PHFs and 
finally in NFTs (Figure 7) (Martin et al. , 2011). When NFTs accumulate in the neurons, 
occupy  to much of the neuron, and apparently promote the neuronal death (Mudher et 
al. , 2002). Regarding this process, the “tangle hypothesis” argues that dysfunction in 
tau homeostasis is a primary event in AD, and that the number of NFTs increases with 
severity of the disease (Kim et al. , 2014).  
Several reports have suggested a relationship between Aβ and tau aggregation. 
One of them, discovered that, after injection of Aβ1-42 into brains of mutant tau mice, 
an increase in the number of NFTs in cell bodies occurred (Gotz et al. , 2001).  
Resuming, the explanation of the cause of AD pathogenesis is extremely 
debated and very controversial, but is far to be discovered.  
1.8. Biomarkers of Alzheimer’s disease 
The diagnosis of AD in an earlier stage of the disease, preferably before starting 
the first aggressive symptoms, is extremely important. However, a definitive diagnosis 
is only possible by examining the neuropathological hallmarks of the disease, at 
autopsy. Therefore, biomarkers are useful to aid in the diagnosis of AD and for the 
determination of disease risk. The autosomal dominantly inherited mutations are 
definite biomarkers of the disease, while the plasma and CSF biomarkers and 
neuroimaging contribute to increasing the specificity of the diagnosis (Sabbagh et al. , 
2013).  
1.8.1. Plasma biomarkers 
Small and lipophilic proteins and some protein transporters able to cross the 
BBB are used as plasma biomarkers (Reitz et al. , 2014). The plasma Aβ1-42 and Aβ1-
40 levels are an example, and data suggested that, in familial AD, the total Aβ levels 
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and Aβ1-42 levels are elevated in plasma, suggesting that this biomarker may be is 
useful in specific subtypes of AD (Ringman et al. , 2008). In addition, Schupf and his 
colleagues suggested that people with high Aβ1-42 levels are at increased risk of AD, 
and with disease progression, levels of some forms of Aβ decline in plasma (Schupf et 
al. , 2008). However, due to the large variability of person-to-person Aβ levels, 
variability in the timing of sample collection across studies and the use of different 
antibodies to detect Aβ, turns the use of this biomarker very controversial (Reitz et al. , 
2014). Regarding this, the use of plasma Aβ1-42/Aβ1-40 ratios is more appropriate to 
help the diagnosis of AD. There is evidence that low plasma Aβ1-42/Aβ1-40 ratios are 
associated with increased risk for MCI and AD (Graff-Radford et al. , 2007).  
Other molecules have been studied as potential plasma biomarkers, including 
cholesterol, homocysteine, IL-1β, TNF, IL-6 and TTR, which role in this pathogenesis 
will be discussed later. 
 
1.8.2. CSF biomarkers 
Due to the direct contact between brain and CSF, Aβ, total tau (t-tau), 
phosphorylated tau (p-tau) and TTR levels, in CSF, are potent biomarkers that can be 
used to aid the diagnosis of AD at an earlier stage of the disease.  
Aβ levels in CSF have been studied by several groups, showing that Aβ1-42 
levels are reduced in the CSF of patients with MCI or AD when compared to individuals 
with normal cognitive functions. The reduction in Aβ clearance from brain to the 
blood/CSF and consequently aggregation and deposition of Aβ into neuritic plaques 
may be an explanation to these low levels in CSF (Humpel, 2011). On the other hand, 
Aβ1-40 levels do not appear to be changed in AD CSF. Therefore, it has been 
suggested that the Aβ1-42/Aβ1-40 ratios can be used to differentiate AD patients from 
non-AD patients (Humpel, 2011). Contrary the Aβ1-42 levels, the t-tau and p-tau levels 
are increased in AD patients as compared with non-AD patients and t-tau seems to be 
a good marker with high sensitivity and specificity in predicting progression from MCI to 
AD (Rosen et al. , 2013).  
Several studies reported TTR as a potential biomarker in AD. It has been 
suggested that TTR levels in CSF are decreased in AD patients relatively to patients 
without dementia (Merched et al. , 1998; Castano et al. , 2006; Gloeckner et al. , 2008). 
The relation between TTR and AD will be further discussed in this section. 
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Additional CSF markers, such as albumin, angiotensin cystatin C, thioredoxin 
and β-secretase, have been explored but the results are inconsistent leaving their 
predictive value as biomarkers unclear (Reitz et al. , 2014).  
 
1.8.3. Neuroimaging as biomarker of AD 
Currently, neuroimaging techniques have been used in early diagnosis of AD. 
One of the methods developed is  the positron emission tomography (PET) (Sabbagh 
et al. , 2013). Briefly, the PET technique is used to identify the amyloid deposition in 
brain in vivo using FDA-approved 11C Pittsburgh Compound B (11C-PIB) as specific 
tracer. Other AD imaging modalities are magnetic resonance imaging (MRI), functional 
magnetic resonance imaging (fMRI) and single photon emission computed tomography 
(SPECT). The validity and specify of these imaging biomarkers of Aβ deposition is 
supported by post-mortem analysis (Reitz et al. , 2014). 
 
2. Blood-Brain Barrier and Alzheimer’s disease 
The accumulation of Aβ in brain seems to start when an imbalance between its 
production and clearance occurs, leading to its aggregation and subsequent deposition 
into neuritic or senile plaques. Therefore, the clearance of Aβ across the BBB 
represents an important aspect of the AD and a therapeutic target (Nazer et al. , 2008). 
It is of crucial importance characterize BBB and understand which BBB pathways are 
affected in this neurodegenerative disorder. 
2.1. The blood-brain barrier  
The two major parts of nervous systems are CNS and PNF, and these are 
separated by two main biological barriers: BBB and blood-cerebrospinal fluid barrier 
(BCSFB) (Marques et al. , 2013). Alterations in morphology and functions of these 
barriers can disrupt the CNS homeostasis (Abbott et al. , 2010).  
The BBB is a multicellular vascular structure and represents a problematic 
obstacle for a large number of biological molecules and drugs due to its impermeability. 
Only small lipophilic molecules, such as O2 and CO2, and a few drugs (barbiturates and 
ethanol) are capable to cross the different types of cells which comprise BBB (Abbott et 
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al. , 2006). Another physiological function of the BBB is providing essential nutrients 
and protects the brain from xenobiotics (Abbott et al. , 2006).  
This barrier is composed by several distinct types of cells including endothelial 
cells (ECs) of cerebral capillaries and microvessels, pericytes and glial cells 
(astrocytes, microglia and oligodendrocytes), and also formed by tight junctions (TJ) 
and adherent junctions (AJ) (Figure 8). These components provide structure and 
functional support to the BBB (Obermeier et al. , 2013).  
 
2.1.1. Cellular composition of the BBB 
Cerebral endothelial cells, one of the components of BBB, have morphological 
characteristics of peripheral endothelial cells and epithelial cells. The ECs shows, 
among other features, an interconnection with TJ and AJ, very low pinocytotic and 
transcytotic activity, and elevated number of mitochondria signifying that these cells 
require a lot of energy (Wilhelm et al. , 2014). One of the most important functions of 
these cells is the creation of a paracellular barrier for ions, proteins and other 
molecules, and the maintenance of the vessel wall and circulatory function (Sumpio et 
al. , 2002).  
Pericytes are randomly distributed along the cerebral capillaries and partially 
surround the endothelium. Both the ECs and the pericytes are enclosed by a local 
basement membrane, which contribute to form a perivascular extracellular matrix layer 
(basal lamina-BL1, Figure 8), used as an anchoring and signaling site for cell-cell 
interactions (Abbott et al. , 2010; Neuhaus et al. , 2010). The role of pericytes seems to 
be in BBB integrity and cerebral microcirculation, survival, migration and endothelial 
proliferation (Bell et al. , 2009; Neuhaus et al. , 2010). These cells secrete many 
molecules that influence the endothelial function, including growth factors (transforming 
growth factor beta (TGF-β) and vascular endothelial growth factor (VEGF)) and 
angiopoetin-1 (Wilhelm et al. , 2014). 
The astrocytes are essential in the maintenance of the BBB due to their 
influence on ECs. The perivascular endfeet of astrocytes (Figure 8), which surround 
the endothelial cells and share the basal lamina, provide the biochemical support to 
ECs cells. These astrocytic feet express several molecules at their perivascular space, 
including glucose transporter 1 (GLUT-1), ABCB1, aquaporin-4, connexin-43, and the 
kir 4.1 K+ channel (Wilhelm et al. , 2014). Astrocytes are able to synthesize several of 
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glia-derived factors, including TGF-β, glial-derived neurotrophic factor (GDNF), basic 
fibroblast growth factor (bFGF) and angiopoetin 1. These biologically active molecules 
seem to influence in endothelial cells (Abbott et al. , 2006).  
 
2.1.2. Junctional complex of the BBB 
The BBB creates a “physical barrier” composed by a network of a variety of tight 
junctions and adherens junctions between adjacent endothelial cells (Figure 9) (Abbott 
et al. , 2006). These interendothelial junctions have a crucial role in restriction of the 
paracellular diffusion of the macromolecules and polar solutes between brain and 
endothelial cells (Luissint et al. , 2012). 
The molecular complex of the TJ exhibits a co-interacting group of adaptor 
proteins, which mediates the cell-cell communications and the cytosketal tethering, 
such as zonula occludens (ZO-1, ZO-2 and ZO-3), 7H6, AF6, vinculin and cingulin 
(Cummins, 2012). The overall junctional complex comprises several transmembrane 
TJ proteins including occludin, MarvelD2 (tricellulin), MarvelD3, claudin and junctional 
adhesion molecules (JAMs) (Wilhelm et al. , 2014). The first integral TJ protein 
discovered was occludin, in 1993 (Furuse et al. , 1993). Occludin is a 60-65 kDa 
protein with multidomain tetraspan structure and two extracellular loops (Hartsock et al. 
, 2008). The C-terminal of occludin is essential to interact with ZO-1 and subsequently 
to help its intracellular trafficking to the plasma membranes and also to mediate its 
dimerization. This TJ protein also displays a MARVEL domain composed by a four-
Figure 8 – Schematic representation of the cellular and molecular composition of the BBB. Abbott et al. , 2010 
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transmembrane structural motif common among junctional proteins involved in 
membrane apposition and fusion events. MARVELD3 and MARVELD2 also exhibit this 
domain (Cummins, 2012). In addition to the occludin TJ, the claudins are other type of 
TJ and also belong to the tetraspan family  (Wilhelm et al. , 2014).  These proteins, with 
molecular weights between 20 and 27 kDa, have an important role in maintaining the 
paracellular barrier and in pore formation. At BBB level, claudins-1,-3,-5 and -12 have 
been shown to contribute to the formation of the TJs between microvascular 
endothelial cells. However the most important isoform is claudin-5 because its absence 
provokes the opening of the BBB for molecules smaller than 800 Da (Schrade et al. , 
2012). Additionally, the JAMs proteins are other group that participate in formation and 
maintenance of the TJ, and belong to the immunoglobulin (Ig)-superfamily. These 
proteins are composed by a single transmembrane domain and two extracellular loops. 
There are three known JAMs (JAM-A, JAM-B and JAM-C), but the best characterized 
is JAM-A. This junctional adherent molecule has a crucial role in the determination of 
the paracellular permeability (Abbott, 2002; Wilhelm et al. , 2014). 
The adherens junctions are the last structures which comprise the junctional 
complex. These proteins are responsible for cell-cell adhesion, stabilization of the actin 
cytoskeleton, intracellular signaling and transcriptional regulation. This group of 
proteins is composed by transmembrane protein E-cadherin, and members of catenin 
family, such as p-120-catenin, β-catenin and α-catenin. All these proteins are 
responsible for controlling the formation, maintenance and function of adherens 
junctions (Hartsock et al. , 2008).  
Resuming, all junctional complex, composed by these several distinct proteins, 
is a dynamic structure responsible for the maintenance of the cellular permeability 
regulated by a sophisticated signaling network (Wilhelm et al. , 2014).  
 
 
 
 
 
 
 
Figure 9 –Representation of composition of junctional complex of the BBB.  Endotheliall 
cells of the BBB are interconnected by a network of tight and adherens junctions. Adapted 
from Wilhelm et al. , 2014. 
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2.2. Transport at BBB 
The maintenance of the homeostasis is supported by the selective transport of 
the nutrients into the brain and the exclusion of xenobiotics out of the brain. The 
transport across the BBB is made by specific transport systems (Figure 10) present on 
the luminal (apical membrane or blood) and the abluminal (or basolateral membrane or 
brain) membranes. Generally, most of the transporters are members of the solute 
carrier family (SLC) or members of active and energy-dependent ATP binding cassette 
(ABC) transporter family (Neuhaus et al. , 2010).  
One of the main types of transport is the passive diffusion, where solutes can 
diffuse through the membranes of the endothelium and enter in the brain passively 
(Abbott et al. , 2010). The lipophilicity favors this process and lipidic molecules, in 
general, show higher permeability (Neuhaus et al. , 2010). Thus, molecules from blood 
gases such as O2 and CO2, and non-polar molecules perform this type of transport at 
the BBB.  
In addition, the removal of metabolites and toxic molecules is made by active 
efflux (with consumption of ATP) from the brain and the BBB by members of the ABC 
transporters family (Neuhaus et al. , 2010). These transporters are a superfamily of 
proteins and the main ABC transporters are P-glycoprotein (P-gp, Multidrug resistance 
Protein, ABCB1/MRDR1), the multi-drug resistance-associated proteins (MRPs, 
ABCC1, 2, 4, 5 and possibly 3 and 6) and ABCG2/BCRP (Breast cancer resistance 
protein). Regarding this, the first discovered export pump at the BBB was P-gp, 
localized in the luminal brain membranes, and its major role is protection of the brain 
from neurotoxic endogenous molecules (Cordon-Cardo et al. , 1989; Abbott et al. , 
2010). In general, the function of these ABC transporters is the neuroprotection by 
detoxifying the brain (Abbott et al. , 2010).  
Due to its polarity, several nutrients and biological molecules cannot across the 
BBB freely. However, these nutrients are extremely necessary for metabolism. 
Therefore, the BBB endothelium shows a number of specific solute carriers to supply 
the CNS with these substances (Abbott et al. , 2010). Many of these transporters 
belong to the SLC superfamily, which comprises 55 gene families with at least 362 
putatively functional protein-coding genes. These several genes can express distinct 
types of carriers such as passive transporters, symporters and antiporters, as well as 
mitochondrial and vesicular transporters (He et al. , 2009). The most abundantly 
expressed SLC carriers are SLC2A1, SLC7A5, SLC16A1, SLC1A3 and SLC1A2 
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(Shawahna et al. , 2011). Specifically, the SLC2A1 (GLUT-1 transporter) is the glucose 
transporter, which is transported by facilitated diffusion.  However, other substrates are 
transported by this group of SLC including amino-acids and oligopeptides, cations and 
anions, bile salts, essential metals, neurotransmitters, vitamins, fatty acids and lipids, 
nucleosides, ammonium, choline, thyroid hormone and urea (He et al. , 2009). 
At last, some substances are transported across the BBB endothelium by 
endocytosis, although the brain endothelium presents lower levels of this process 
compared with peripheral capillaries. However, the transport of too large molecules - 
peptides and proteins – is made via a vesicular route, either by a specific receptor 
mediated transcytosis (RMT) or by non-specific adsorption-mediated transcytosis 
(AMT), and in most cases, molecules can be transcytosed by adsorption to the clathrin-
coated or caveolar vesicle membrane. Thus, the RMT is active by a specific interaction 
with RMT receptors expressed on brain ECs, and the main ligands are insulin, 
transferrin, LDL-cholesterol, leptin and insulin-like growth factors (IGF-I and IGF-II). By 
contrast, the AMT is triggered by an electrostatic interaction between a cationic 
substance and negatively charged luminal membrane of the ECs.  (Herve et al. , 2008; 
Neuhaus et al. , 2010).  
Several of these types of transporters are involved in the flux of Aβ peptide 
across the BBB being the receptor-mediated transport, the main responsible for 
transport of Aβ. 
 
 
Figure 10 – Scheme of several routes of transport across the BBB. Abbott et al. , 2010 
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2.3. Aβ clearance across the BBB 
The clearance of Aβ from the brain takes place by three distinct pathways: 
transport across the BBB, proteolytic degradation (by action of Neprilysin (NEP) and 
insulin-degrading enzyme (IDE)) in the brain and bulk flow of CSF (Bell et al. , 2009; 
Grimm et al. , 2013; Qosa et al. , 2014). In this topic will be discussed the mechanism 
that occurs at the BBB.  
The efficiency of Aβ clearance from brain interstitial fluid (ISF) across the BBB 
is influenced by several Aβ binding transport proteins such as ApoE and ApoJ 
(clusterin), TTR and α-2-macroglobulin (α2M) and BBB receptors, including LRP1 and 
receptor for advanced glycation end products (RAGE) and Aβ degrading enzymes 
(Deane et al. , 2009).  
 
2.3.1. Receptor-mediated transport 
Aβ is transported bidirectionally across the BBB (Figure 11): brain-to-blood and 
blood-to-brain directions (Banks et al. , 2005).  
The main receptor of the BBB responsible for the efflux of Aβ is LRP1. This 
receptor mediates Aβ transcytosis across the BBB and the process initiates at the 
abluminal side of the endothelium and, then is directly eliminated from brain into 
bloodstream (Shibata et al. , 2000; Zlokovic, 2004). LRP1 is a ~600 kDa receptor, a 
member of the low-density lipoprotein (LDL) receptor family (Donahue et al. , 2006). It 
is composed by an extracellular domain (heavy α-chain, 515 kDa), a transmembrane 
domain (85 kDa) and cytoplasmatic light β-chain domain). The α-chain has four ligand-
binding domains (clusters I-IV), consisting of 2, 8, 10 and 11 cysteine-rich complement 
repeats, respectively. In addition to Aβ, the domains II and IV bind over forty ligands 
and include the next classes: lipoproteins, coagulation factors, growth factors, 
extracellular matrix proteins, chaperones and bacterial/viral proteins (Nazer et al. , 
2008). The cytoplasmatic chain is composed by two NPXY motifs, one YXXL motifs 
and two di-leucine motifs (Li et al. , 2001; Deane et al. , 2009). This shorter 
cytoplasmitic tail is phosphorylated on serine and/or tyrosine residues, which interacts 
with distinct adaptor proteins such as disabled-1 (Dab-1), FE65 and postsynaptic 
density protein 95 (PSD95) (Kanekiyo et al. , 2014). Thus, in the CNS, LRP1 has a 
critical role as scavenger and transporter and a transmembrane cell signaling receptor.  
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Briefly, the removal of Aβ from the brain initiates when Aβ binds to the LRP1 at 
the endothelial membrane and crosses the BBB to the blood. Then, in bloodstream the 
free Aβ is sequestered by soluble LRP (sLRP), which is the truncated extracellular 
domain of LRP1, and recognized as major endogenous peripheral “sink” agent of Aβ. 
Finally, the circulating Aβ is degraded in the liver and also in the kidney (systemic 
clearance). (Bell et al. , 2009).  
Additionally, Aβ peptide seems to have other transporters such as P-gp and 
LRP2. It was suggested that LRP2, also called megalin/gp330 receptor, is involved in 
efflux of Aβ, when this peptide forms a stable complex with the ApoJ (Bell et al. , 2007). 
Relatively to the P-gp, an ATP-dependent efflux pump expressed on the luminal 
surface of brain endothelium, one in vivo study demonstrated that when [125I]Aβ1-40 
and [125I]Aβ1-42 was injected into the CNS of P-gp-null mice, the rate of clearance was 
half of that in controls mice. Furthermore, in the same study, APP transgenic mice 
treated with P-gp inhibitor demonstrated increased levels of Aβ within brain ISF 
compared with non-treated ones (Cirrito et al. , 2005). Thus, P-gp seems to cooperate 
with LRP in transport of Aβ out of the brain (Jeynes et al. , 2013). However, the 
mechanisms of efflux by P-gp and megalin remains unclear (Sagare et al. , 2013). 
On the other hand, RAGE receptor is implicated in the Aβ influx into the brain 
from the periphery (Deane et al. , 2003). RAGE is a multiligand receptor of the 
immunoglobulin superfamily, located on the luminal membrane of the brain 
endothelium (Deane et al. , 2009). Furthermore, RAGE is a 45 kDa receptor comprising 
three immunoglobulin domains (one V-type and two C-type) followed by a single 
transmembrane region, and a short C-terminal cytoplasmatic tail (Park et al. , 2010; 
Sagare et al. , 2013). The extracellular V-domain is necessary to the interaction with 
several ligands such as AGE proteins, S100/calgrulins, monomeric and oligomeric Aβ, 
amphoterin, and the family of crossed β-sheet macromolecules (Yan et al. , 2010). 
Summarizing, the balance between RAGE and LRP1 receptors, the main Aβ 
transporters across the BBB, is extremely important to maintain Aβ physiological levels. 
Any alterations in these receptors or proteins related to them can provoke BBB 
dysfunction and impaired clearance of Aβ from the brain  
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2.4. BBB dysfunction and AD 
In AD, one of the possible reasons for the accumulation of Aβ peptide into 
amyloid plaques is an impaired clearance of this peptide across the BBB (Mawuenyega 
et al. , 2010). It has been suggested that imbalance of Aβ clearance may be caused by 
alterations in Aβ BBB receptors, such as LRP1, RAGE and P-gp (Figure 12). 
As mentioned above, LRP1 mediates the efflux of Aβ peptide out of the brain. 
Clearly, failure in this transport leads to an increase of Aβ deposition in the brain. 
Several studies demonstrated that LRP1 expression in brain endothelium decreases 
with aging in rodents, as well as in AD models and AD patients (Shibata et al. , 2000; 
Deane et al. , 2004; Donahue et al. , 2006; Bell et al. , 2009). Thus, one of the 
possibilities for Aβ accumulation is down-regulation of LRP1. Moreover literature 
Figure 11 – Schematic representation of the mechanism of the Aβ clearance across the BBB. Aβ transport is 
mediated by several pathways: (1) central and (2) systemic production of Aβ from its precursor APP; (3) oligomerization 
and aggregation; (4) influx of Aβ mediated by RAGE; (5) efflux of Aβ across BBB by LRP1; (6) interaction between ApoJ 
/ApoE and Aβ; (7) efflux of Aβ mediated by megalin (LRP2); (8) efflux of Aβ mediated by P-gp receptor; (9)enzymatic 
degradation of Aβ  by NEP and IDE; (10) cellula degradation by glial cells; (11) Aβ transport in choroid plexus; (12) Aβ 
removal via ISF-CSF bulk flow; (13) Sequestration of Aβ  by sLRP1; (14) Aβ systemic clearance at liver and kidney. Bell 
et al. , 2009 
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reports that the expression of LRP is negatively regulated by Aβ levels (Wang et al. , 
2006).  
Other important evidence in AD is a decreased expression of the P-gp Aβ 
transporter with increased Aβ levels in AD brain, which seems to progressively 
contribute to Aβ accumulation (Vogelgesang et al. , 2002).  
By contrast, when Aβ accumulates in AD brain, RAGE expression increases in 
microvessels, neurons or microglia (Yan et al. , 1996). The up-regulation of RAGE 
leads to excessive amounts of Aβ in AD brain through a positive-feedback mechanism 
(Shibata et al. , 2000). The interaction Aβ/RAGE in AD seems to mediate a relevant 
neuronal dysfunction, inflammatory responses in the endothelium, NF-КB-dependent 
apoptosis and finally neuronal death (Deane et al. , 2009).  
Thus, decreased expression of Aβ efflux transporters at the BBB (LRP1 and P-
gp) and increased expression of Aβ influx transporter RAGE seems to contribute to Aβ 
accumulation in the brain by imbalance in the clearance pathway at the BBB.  
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 12 – Alterations at the BBB in aging and AD. Adapted 
from Marques et al. , 2013 
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3. Transthyretin  
Several molecules have been suggested as Aβ carriers and among them TTR 
has received special attention (Schwarzman et al. , 1994). TTR was first described by 
Seibert and Nelson, in 1942, as an X component with a slightly mobility greater than 
albumin (Seibert; et al. , 1942). TTR is mainly synthetized in the liver and in the choroid 
plexus of the brain, being secreted into the plasma (3-7 µM) and CSF (0.1-0.4 µM), 
respectively (Soprano et al. , 1985; Yang et al. , 2013). 
3.1. TTR structure and functions 
Initially, TTR was designated as prealbumin, but its current name is derived 
from its mains physiological functions: transport of the thyroid hormone thyroxine (T4) 
and retinol (vitamin A), through the binding of retinol binding protein (RBP) (Power et 
al. , 2000; Costa et al. , 2008a). Besides its well-known transport capabilities, another 
TTR function was described by Liz et al. proposing that TTR might be a protease able 
to cleave apolipoprotein A1 (ApoA1) in vitro,  and later suggested that TTR is also 
capable to cleave lipidated ApoA1 and that this cleavage decreases its ability to 
promote the efflux of cholesterol (Liz et al. , 2004; Liz et al. , 2007). Moreover, Costa 
and co-workers showed for the first time that Aβ peptide is cleaved by TTR (Costa et 
al. , 2008a). Newly, Liz et al. also characterized TTR as a metallopeptidase, and more 
recent FRET study confirmed this recently described inducible mechanism proposed 
for TTR based on 3D structure in presence of Zinc and a series of point mutations (Liz 
et al. , 2012; Gouvea et al. , 2013).  
Structurally, TTR is a 55 kDa homotetrameric transport protein and each 
monomer has two four-strand β-sheets, composed by an inner sheet of strands D, A, G 
and H, and an outer sheet of strands C, B, E and F, as well as a small α-helix and a 
loop that connects strands E and F. The assembly of the monomer into dimers is 
stabilized by an extensive hydrogen bonding and subsequently assembly of two dimers 
linked by hydrogen bonds and hydrophobic bonds between loop AB from one dimer 
and strand H from the other dimer. Consequently, tetramer assembly (Figure 13) forms 
a hydrophobic channel where T4 binds, while retinol binds at surface of the protein and 
does not interfere with T4 binding (Morais-de-Sa et al. , 2004; Yang et al. , 2013). The 
specific domains on TTR involved in Aβ/TTR binding were probed by Du et al. in 2012. 
This study demonstrate by an array method that Aβ binds strongly to TIAALLSPYSYS 
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(residues 106-117) sequence that correspond to strand G on the inner β-sheet of TTR, 
but a weakly bound was also detected in residues 59-83, which includes strand E 
through the E/F helix and loop (Du et al. , 2012).  
 
 
 
 
 
 
 
 
3.2. TTR as cause of disease 
Besides its protective role in AD, which will be debated forward, TTR is also 
associated with disease, in particular with amyloidosis, a group of disorders defined by 
the formation and aggregation of misfolded proteins which leads to its accumulation in 
distinct organs (Westermark et al. , 2007). The main syndromes associated to TTR 
aggregation are senile systemic amyloidosis (SSA), familial amyloidotic polyneuropathy 
(FAP) and cardiomyopathies (FAC) (Buxbaum et al. , 2009).  
The main amyloidotic disorder associated to TTR is FAP. This disorder was 
described more than 60 years ago by the Portuguese professor Corino de Andrade 
(Andrade, 1952) and TTR was identified as principal component present in deposits of 
FAP patients in 1978 (Costa et al. , 1978). Thus, FAP is a hereditary autosomal 
dominant disease characterized by deposition of fibrils especially in PNS, and the most 
common mutation that cause FAP is the substitution of a valine residue for a 
Figure 13 – Structure of homotetrameric TTR. The colour red shows Leucine 82 
on end of EF strand and blue shows leucine 110 on strand G. Yang et al. , 2013 
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methionine at position 30 (V30M), however more than 100 mutations are currently 
known (Saraiva et al. , 1984; Fleming et al. , 2009b). 
3.3. TTR in the nervous system  
It has been demonstrated that TTR has several neuroprotective properties in 
numerous contexts. Studies with TTR null mice revealed reduced signs of depressive-
like behavior, probably due to the modulation of noradrenergic system by the increase 
of noradrenaline in the limbic forebrain (Sousa et al. , 2004). Additionally, increased 
levels of NPY, known as an antidepressant neurotransmitter (Heilig, 2004), in dorsal 
root ganglia (DRG), sciatic nerve, spinal cord, hippocampus, cortex and CSF were also 
found in TTR-/- mice (Nunes et al. , 2006), supporting the importance of TTR in the 
modulation of depressive behavior. Furthermore, Sousa and co-workers also described 
that TTR-/- mice showed memory impairment compared with TTR+/+ animals, indicating 
that the absence of TTR accelerate cognitive deficits usually associated with aging 
(Sousa et al. , 2007).  
In addition, TTR was associated to nerve regeneration. Fleming et al. revealed, 
for the first time, that TTR can act as a nerve regeneration enhancer by the observation 
that TTR-/- mice presented a decrease in regeneration of a sciatic crushed nerve 
(Fleming et al. , 2007). Later, the same authors showed that absence of TTR leads to 
impaired retrograde transport and decreased axonal growth, and also that the effect of 
TTR in neurite outgrowth and nerve regeneration is mediated by megalin-dependent 
internalization (Fleming et al. , 2009a).  
It was also established a relationship between TTR and ischemia, one of the 
major causes of brain injuries in world. Santos and co-workers proposed that in a 
compromised heat-shock response, CSF TTR contributes to control neuronal cell 
death, edema and inflammation, influencing the survival endangered neurons (Santos 
et al. , 2010). 
More recently, a new role for TTR was proposed in CNS, as a transcription 
inducer of insulin-like growth factor receptor I (IGF-IR), known as a protective receptor 
against apoptosis (Kooijman, 2006). Vieira and colleagues described, for the first time, 
that TTR induces increased levels of IGF-IR, and they also showed, using a GFP-IGF-
IR fusion protein, that TTR triggers IGF-IR nuclear translocation in cultured neurons, 
unveiling a new neuroprotective role for TTR (Vieira et al. , 2014). 
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3.4. TTR and its protective role in AD 
Schwarzman and co-workers described TTR as the major Aβ binding protein in 
CSF, able to inhibit Aβ aggregation and toxicity, suggesting that when TTR fails Aβ 
sequestration, amyloid formation occurs (Schwarzman et al. , 1994; Schwarzman et al. 
, 1996). The importance of TTR in AD is supported by the observation that TTR is 
decreased in CSF of AD patients (Hansson et al. , 2009); Ribeiro et al. and others 
showed that TTR is also decreased in plasma/sera from AD patients (Han et al. , 2011; 
Ribeiro et al. , 2012a; Velayudhan et al. , 2012). Importantly, this decrease is observed 
early in disease development as indicated by the lower plasma TTR levels measured 
not only in AD patients but also in patients with MCI; it is also reported that TTR levels 
correlate with disease state, prompting TTR as an attractive early biomarker (Ribeiro et 
al. , 2012a). Very recently, researchers have identified 10 plasma proteins, including 
TTR, strongly associated with disease severity and disease progression (Hye et al. , 
2014). In addition, data from transgenic mice has shown that APPswe/PS1∆E9 mice 
exposed to an enriched environment presented reduced signs of AD-like 
neuropathology and altered expression of several genes including upregulation of TTR 
(Lazarov et al. , 2005). Moreover, AD transgenic mouse models with genetically altered 
TTR levels provided evidence (although sometimes conflicting) for a critical role of TTR 
in AD (Choi et al. , 2007; Buxbaum et al. , 2008; Wati et al. , 2009; Oliveira et al. , 
2011). Oliveira and co-workers provided evidence for  gender-associated modulation of 
brain Aβ levels by TTR and suggested that female transgenic AD/TTR mice with one 
copy of TTR gene has elevated Aβ levels in the brain when compared to female 
transgenic AD/TTR mice with two copies of the TTR gene. This report demonstrated 
also that TTR reduction influences brain levels of 17β-estradiol in a gender-associated 
manner (Oliveira et al. , 2011). Interestingly, Ribeiro et al. evaluated TTR levels in 
plasma of MCI/AD patients and showed that AD women presented lower TTR levels 
compared to women control. However, MCI and AD men did not present significant 
differences compared to control men, further supporting a gender-associated 
modulation by TTR in AD (Ribeiro et al. , 2012a). 
Regarding the nature of TTR/Aβ interaction, several researchers confirmed the 
binding between TTR and Aβ as well as the possibility of binding to the distinct Aβ 
species. Buxbaum and co-workers demonstrated that TTR has the capacity to bind 
toxic Aβ aggregates in extracellular and intracellular environment in a chaperone-like 
manner (Buxbaum et al. , 2008). Liu and Murphy also described binding of TTR to 
aggregated forms of Aβ (Liu et al. , 2006). Other reports confirmed the role of TTR as 
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an Aβ binding protein and also showed, using competition binding assays that TTR 
binds to different Aβ species including soluble, oligomers and fibrils. Additionally, Costa 
et al. demonstrated that TTR is capable of interfering with Aβ fibrillization by inhibiting 
and disrupting fibril, suggesting the inhibition/disruption of Aβ fibrils as a possible 
protective mechanism underlying the protective role of TTR in AD (Costa et al. , 
2008b). Supporting the hypothesis that TTR binds to Aβ, in another report, Costa et al. 
demonstrated that TTR (recombinant and isolated from human sera) is capable to 
cleave Aβ in multiple positions (Costa et al. , 2008a). 
Understanding which TTR conformation binds to Aβ is an important discussion 
between investigators. Some authors argued that Aβ monomers bind preferentially to 
the TTR in monomer form (Du et al. , 2010; Yang et al. , 2013) while other investigators 
claim the opposite (Schwarzman et al. , 2004; Ribeiro et al. , 2012b). In fact, Yang and 
his co-workers proposed one novel mechanism of action for TTR: when EF helix/loop 
of the TTR “feels” the presence of soluble toxic Aβ oligomers triggers an destabilization 
of the TTR tetramer and subsequently exposes the hydrophobic inner sheet, which 
leads to the scavenging of the oligomers (Yang et al. , 2013). Differently, other 
investigators claim that the tetramer is essential for Aβ binding and that unstable TTR 
mutations (in which dissociation of the tetramer occurs) do not bind or bind poorly to Aβ 
(Schwarzman et al. , 2004; Ribeiro et al. , 2012b). 
As mentioned previously, TTR mutations are associated with FAP, a systemic 
amyloidosis with a special involvement of the peripheral nerve. It is believed that the 
amyloidogenic potential of the TTR variants is related to a decrease in tetrameric 
stability and it is thought that dissociation of the tetramer into monomers is the basis of 
a series of events that leads to the formation of TTR amyloid (Cardoso et al. , 2002). 
Thus, TTR stabilization has been proposed as a key step for the inhibition of TTR fibril 
formation and has been the basis for FAP therapeutic strategies (Almeida et al. , 2005). 
Such stabilization can be achieved through the use of small compounds sharing 
molecular structural similarities with T4 and binding in the T4 central binding channel 
(Almeida et al. , 2004; Morais-de-Sa et al. , 2004). 
To further gain insights into the factors affecting TTR decrease in AD, plasma 
TTR binding to T4 was assessed and authors found a decreased ability of the protein to 
carry T4 in AD patients, indicating that this function of TTR is impaired (Ribeiro et al. , 
2012a). This observation indicates that TTR is destabilized and its clearance 
accelerated, explaining the lower levels found in AD. It was then hypothesized that TTR 
stabilization may be a key factor in the TTR/Aβ interaction as also previous works 
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showed that TTR amyloidogenic variants bind less to Aβ peptide (Costa et al. , 2008b). 
Authors then proposed that the use of small compounds known to stabilize the TTR 
tetrameric fold should result in improved TTR binding to Aβ, and could be used as 
potential therapeutic strategies in AD: drugs such as iododiflunisal (IDIF), resveratrol, 
dinitrophenol (DNP), 2-((3,5Dichlorophenyl) amino) benzoic acid (DCPA) and 4-(3,5-
difluorophenyl) (DFPB), were tested and found to strengthen TTR/Aβ interaction 
(Ribeiro et al. , 2012b). In addition, the effects of one of such drugs – IDIF – were 
studied in vivo in an AD mouse model (Ribeiro et al. , 2014). The results showed that 
IDIF administered orally bound TTR in plasma and stabilized the protein, and was able 
to enter the brain. Further, IDIF administration resulted not only in decreased brain Aβ 
levels and deposition but also in improved cognitive function associated to the AD-like 
neuropathology in this mouse model.  Aβ levels were reduced in plasma and presented 
a trend for reduction in the CSF, suggesting TTR promoted Aβ clearance from the brain 
and from the periphery (Ribeiro et al. , 2014). 
Very recently, it has been shown TTR expression in neurons and some hints on 
its regulation have already been advanced. Kerridge and colleagues showed that TTR 
is expressed in SH-SY5Y neuroblastoma cell line, and that it is up-regulated by the 
AICD fragment of APP, specifically derived from the APP695 isoform (Kerridge et al. , 
2014). Induced accumulation of functional AICD resulted in TTR up-regulation and Aβ 
decreased levels. Wang and colleagues reported that TTR expression in SH-SY5Y 
cells, primary hippocampal neurons and the hippocampus of APP23 mice is 
significantly enhanced by heat shock factor 1 (HSF1) (Wang et al. , 2014). 
The expression of TTR by neurons, together with the observation of Aβ reduced 
levels in plasma and CSF upon IDIF treatment (Ribeiro et al. , 2014), lead us to 
hypothesize that TTR might also be involved in Aβ efflux at the BBB. 
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The main goals of this project were to study how TTR exerts its protective role 
in AD, by investigating the influence of TTR in Aβ transport across the BBB, using a 
cellular BBB model and an in vivo study in mice. We also aimed at finding stimulus that 
can induce TTR neuronal synthesis, using a neuronal cell model. The two chapters of 
this project had the following objectives: 
 
1. To investigate the influence of TTR in Aβ transport across the BBB we will: 
 
a. ascertain the effect of TTR in Aβ plasma levels by measuring Aβ1-40 
and Aβ1-42 concentrations in plasma of AD/TTR+/+, AD/TTR+/- and 
AD/TTR-/- female mice, at different ages; 
b. optimize a cellular model for the BBB – Immortalized human cerebral 
microvascular endothelial cell line (hCMEC/D3); 
c. evaluate the influence of TTR in Aβ internalization and efflux by 
hCMEC/D3 cells, using different approaches; 
d. investigate the effect of TTR in hCMEC/D3 basolateral-to-apical 
permeability to Aβ1-42, using a transwell system; 
e. assess the effect of TTR in Aβ clearance in vivo, by injecting FAM-Aβ1-
42 intracranial in mice with different TTR genotypes. 
 
2. To find stimulus that lead to neuronal TTR synthesis, we will: 
 
a. investigate the effect of different Aβ species in TTR and APP genes 
expression using a SH-SY5Y neuroblastoma cell line; 
b. ascertain the influence of 695APPswe isoform in TTR gene expression 
versus the effect of exogenous TTR in expression of APP gene, using 
SH-SY5Y cell line.  
 
  
 
  
 
 
 
 
 
 
 
Chapter I: Exploring the protection of 
Transthyretin in Alzheimer’s disease: effects 
on Aβ peptide clearance at brain-blood 
barrier 
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Material and methods – chapter I 
1. Animals 
The AD mouse model APPswe/PS1A246E/TTR was used for the quantification 
of Aβ levels in plasma at different ages. The colony was generated by crossing 
APPswe/PS1A246E transgenic mice (Borchelt et al. , 1997) (B6/C3H background) 
purchased from The Jackson Laboratoy with TTR-knockout mice (TTR-/-) (SV129 
background) (Episkopou et al. , 1993) as previously described (Oliveira et al. , 2011). In 
this study, we used cohorts of littermates APPswe/PS1A246E/TTR+/+ (carrying 2 copies 
of the TTR gene), APPswe/PS1A246E/TTR+/- (carrying 1 copy of the TTR gene) and 
APPswe/PS1A246E/TTR-/- (without TTR gene) female mice aged 3, 6 and 10 months 
(n=6 for each genotype and age).  
TTR-wild type (+/+), TTR-heterozygous (+/-) and TTR-knockout (-/-) mice in a 
SV129 background (Episkopou et al. , 1993) were obtained from the littermate offspring 
of heterozygous breeding pairs. These animals were utilized for the in vivo brain Aβ1-
42 efflux assay and the study was performed using male mice with 3 months of age 
with different TTR genotypes (n=3). The TTR-wild type (+/+) and TTR-knockout (-/-) 
mice were also used to obtain sera or plasma with different TTR genotypes. 
Animals were housed in a controlled environment (12-h light/dark cycle; 
temperature, 22±2°C; humidity, 45-65%), with freely available food and water. All 
procedures involving animals were carried out in accordance with National and 
European Union Guidelines for the care and handling of laboratory animals.  
In the next sections, the APPswe/PS1A246E/TTR colony will be referred to as 
AD/TTR, and the different genotypes APPswe/PS1A246E/TTR+/+ and 
APPswe/PS1A246E/ TTR+/- referred to as AD/ TTR+/+ and AD/ TTR+/-, respectively. 
2. Blood collection  
Mice were profoundly anesthetized with an anesthetic combination of ketamine 
(75 mg/Kg) and medetomidine (1 mg/Kg) by intraperitoneal injection (IP). Blood was 
collected from the inferior vena cava with syringes with and without EDTA (as 
anticoagulant) to obtained plasma or sera, respectively, followed by centrifugation at 
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1000 rpm for 15 minutes at room temperature (RT). Plasma and sera samples were 
collect and frozen at -80 οC until used.  
All efforts were made to minimize pain and distress; all animal experiments 
were carried out in accordance with the European Communities Council Directive. 
3. Aβ levels quantification  
Plasma Aβ1-42 and Aβ1-40 levels were quantified using Aβ1-42 Human 
Ultrasensitive ELISA Kit and Aβ1-40 Human ELISA Kit (both Invitrogen), respectively, 
according to the manufacturer’s instructions.  
The same ELISA analysis was also used to determine the Aβ1-42 levels in 
upper chamber (or apical side) and lower chamber (or basolateral side) of transwells in 
BBB transport studies.  
4. Preparation of Aβ1-42 peptides 
The Aβ1-42 peptide was purchased from Genscript, dissolved in hexafluoro-2-
propanol (HFIP) and kept at room temperature overnight. The HFIP was removed 
under a stream of nitrogen and the residue was then dissolved in DMSO at 2mM.  
Aβ1-42 labeled with 5-(and-6)-Carboxyfluorescenin (FAM) – FAM-Aβ1-42 – was 
purchased from Anaspec and dissolved in PBS with 1% NH4OH. For in 
vitro experiments, FAM-Aβ1-42 was diluted in Endothelial Cell Growth Medium (EBM-2 
medium) and for in vivo experiments FAM-Aβ1-42 was diluted in Phosphate Buffered 
Saline (PBS).  
5. Recombinant TTR production and purification 
Human recombinant TTR (hrec TTR) was produced in a bacterial expression 
system using Escherichia coli BL21 (Furuya et al. , 1991) and purified as previously 
described (Almeida et al. , 1997). Briefly, after growing the bacteria, the protein was 
isolated and purified by preparative gel electrophoresis after ion exchange 
chromatography. Protein concentration was determined using the Bradford Method 
(Bio-Rad), using bovine serum albumin (BSA) as standard. 
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6. Cell culture 
Immortalized human cerebral microvascular endothelial cell line (the 
hCMEC/D3 cell line) was kindly provided by Dr. P.O. Couraud (Institute Cochin, Paris, 
France). The original brain endothelial cells used for generation of the cell line were 
isolated from the temporal lobe of brain of an adult female with epilepsy. The 
hCMEC/D3 cell line had been immortalized by lentiviral transduction using large SV40 
T antigen (Weksler et al. , 2005).  
Cells were used between passages 25 and 35. Cell culture surfaces were 
coated with rat tail collagen type I solution (Corning life sciences) at a concentration of 
150 µg/mL and incubated for 1 hour at 37οC. For culturing, cells were grown in EBM-2 
medium (Lonza) supplemented with 5% of fetal bovine serum (FBS) (Gibco), 1% of 
penicillin-streptomycin (Lonza), 1,4 µM of hydrocortisone (Sigma), 5 µg/mL of Ascorbic 
acid (Sigma), 1% of chemically defined lipid concentrate (Gibco), 10 mM of 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Gibco) and 1 ng/mL of human 
basic fibroblast growth factor (bFGF) (Sigma). Cells were cultured in an incubator at 
37οC in a humidified atmosphere of 95% and 5% of carbon dioxide (CO2). Cell culture 
medium was changed every 2-3 days. During experiments cells were maintained in 0% 
FBS medium.  
7. Protein extraction 
Proteins from washed hCMEC/D3 cells were extracted in lysis buffer (20 mM 
MOPS pH 7.0; 2 mM EGTA; 5 mM EDTA; 30 mM sodium fluoride; 60 mM β-
glycerophosphate pH 7.2; 20 mM sodium pyrophosphate; 1 mM sodium orthovanadate; 
1% triton X-100), 1 mM phenylmethylsulphonyl fluoride (PMSF) and protease inhibitors 
(GE healthcare) by scraping the cells, followed by 20 minutes on ice. Extracts were 
then centrifuged at 14 000 rpm at 4οC for 20 minutes, and supernatants were used for 
protein analysis. Total protein concentration was quantified in all extracts by the 
Bradford Method (Bio-Rad), using BSA as standard. 
8. TTR depletion from human sera 
Human sera, available in the laboratory from volunteer’s donors, were depleted 
to remove TTR using column affinity chromatography. The first step consisted in the 
coupling of the protein G sepharose beads (GE healthcare) with the polyclonal rabbit 
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anti-human prealbumin (Dako) (2 mg of antibody per mL of beads) during 3 hours with 
shaking. After incubation, the beads were washed and incubated 1 hour with a fresh 
crosslinking solution (20 mM dimethyl pimelimidate (DMP) in 100 mM sodium borate 
pH 9.0) on a shaking plataform. Then, the beads linked to antibody were transferred to 
a column and further incubated with 1 mL of human serum for 2 hours at RT. After 
column packing, the TTR depleted serum was collected followed by elution of TTR 
protein with a suitable Gentle Ag/Ab elution buffer (Thermo Scientific). The TTR 
depletion from human serum was confirmed by 15% SDS-PAGE followed by 
transference to a nitrocellulose membrane as described above. 
9. Western-Blot analysis 
The presence of TTR in human serum after depletion, as well as the expression 
of tight junctions proteins, such as claudin-3 and occludin, and LRP1 by hCMEC/D3 
cells was studied by western blot analysis.  
Protein extract denatured samples (30 µg) were separated (constant amperage 
of 25 mA) by acrylamide/bisacrylamide gel (10% for LRP1 and 15% for claudin-3, 
occludin and TTR) (Bio-rad). After SDS-PAGE, the proteins were transferred (2 hours 
at a constant voltage of 100 V) to nitrocellulose membrane (WhatmanTM Ge healthcare 
– Protan BA 83), using a wet system (Bio-rad Criterion Blotter). The membranes were 
blocked 1 hour at RT with 5% powered skimmed milk in PBS containing 0,05% Tween-
20 (PBS-T). After blocking, membranes were then incubated with primary antibodies in 
3% powered skimmed milk/PBS-T against the proteins under study (table 1). Then, 
washed membranes were incubated for 1 hour at RT with sheep anti-rabbit 
immunoglobulins conjugated with horseradish peroxidase (The binding site; 1:10000) in 
3% powered skimmed milk/PBS-T. The blots were developed using ClarityTM Western 
ECL substrate (Bio-rad) and proteins were detected and visualized using a 
chemiluminescence detection system (ChemiDoc, Bio-rad). When necessary, 
membranes were stripped for 10 minutes at RT with gentle shaking using a commercial 
stripping buffer (RestoreTM Western Blot stripping buffer; Thermo scientific), for re-
utilization of the membranes, according to the manufacturer’s instructions.  
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Table 1. List of antibodies used in Western Blot and immunofluorescence analysis. 
 Western Blot Immunofluorescence 
Protein Primary antibody Dilution Dilution 
Human TTR Polyclonal rabbit anti-
human prealbumin 
(Dako) 
1:2000 - 
LRP1 Polyclonal rabbit 
antibody anti-LRP1 
(H:80) (Santa Cruz 
Biotechnology) 
1:200 1:100 
Claudin-3 Polyclonal rabbit 
antibody anti-claudin-3 
(Invitrogen) 
1:250 1:12.5 
Occludin Polyclonal rabbit 
antibody anti-occludin 
(Invitrogen) 
1:250 1:12.5 
Aβ peptide Rabbit anti-β-amyloid 
antibody 
(Sigma-Aldrich) 
- 1:200 
 
10. Immunofluorescence  
hCMEC/D3 were grown to confluence on glass coverslips (Thermo Scientific) 
coated with  rat tail collagen type I solution. Cells were washed in PBS and fixed with 
ice-cold acetone 10 minutes on ice or PFA for 20 minutes at RT. Fixed cells were 
permeabilized and blocked with 3% BSA and 0,25% Triton X-100 in PBS followed by  
incubation with primary antibodies against the proteins under study (table 1). After 
washing, cells were incubated with Alexa Fluor-488 donkey anti-rabbit IgG antibody 
(Invitrogen, 1:1000). Then, coverslips were mounted with Fluoroshield™ with DAPI 
(Sigma-Aldrich) and visualized and photographed with Zeiss Axio Imager Z1 equipped 
with an Axiocam MR3.0 camera and Axiovision 4.7 software.  
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11. In vitro Aβ1-42 uptake assays 
11.1. Flow cytometry analysis  
For quantification of Aβ1-42 uptake by flow cytometry, stable hCMEC/D3 cells 
were plated into a 6-well plate coated with collagen type I and grown to confluence. 
Cells were washed with PBS and incubated for 3 hours at 37οC with 500 ng/mL of 
FAM-Aβ1-42 in presence or absence of TTR, through the addition of 2.5% human 
serum or 2.5% TTR depleted serum (obtained as previously described), respectively, 
or using 2.5% recombinant TTR. After incubation, cells were washed twice with PBS 
and enzymatically detached using trypsin (Gibco), and then, suspension cells were 
centrifuged at 1000 rpm at RT for 5 minutes. The pellet was washed with PBS and cells 
centrifuged as described above. Then, the pellet was resuspended with PBS, and if 
necessary fixed with 4% PFA. Finally, cells were analyzed in FACS Canto II equipment 
(BD Biosciences) using Blue laser excitation of 488 nm. The flow cytometry data were 
analysed using Flowjo workstation available at IBMC.  
11.2. Fluorescence microscopy 
Imaging experiments of Aβ1-42 uptake by hCMEC/D3, cells were grown to 
confluence on coated glass coverslips. Hereafter, cells were exposed to 500 ng/mL of 
FAM-Aβ1-42 during 3 hours at 37οC in presence or absence of TTR (2.5% human sera 
and 2.5% TTR depleted sera, respectively). After incubation, cells were washed with 
PBS and then fixed with ice-cold acetone for 10 minutes on ice, and posteriorly 
mounted with Fluoroshield with DAPI. 
Aβ1-42 uptake assay was also performed using mice sera obtained from mice 
of different genotypes for TTR. Thus, cells were incubated with 500 pg/mL Aβ1-42 for 3 
hours at 37°C with TTR(-/-) and TTR(+/+) sera (2.5% for both sera). For this assay, the 
primary antibody used against Aβ peptide was rabbit anti-β-amyloid antibody (table 1), 
and the immunostaining protocol was done as described above in immunofluorescence 
topic and all the coverslips were visualized with Zeiss Axio Imager Z1. 
FCUP/ICBAS 
Material and methods-chapter I 
79 
 
12. Uptake and efflux of Aβ1-42 – Fluorometric assay 
Fluorescence assay was performed using hCMEC/D3 cells cultured onto 
collagen type I coated 24-wells.  
Briefly, for the uptake assay, cells were washed twice with PBS and then, 
incubated at 37οC with 500 ng/mL FAM-Aβ1-42, in presence or absence of 2.5% 
hrecTTR, for 3, 5, 10, 15 and 30 minutes. After this, incubation media (supernatants) 
were collected and the cells were washed twice with PBS followed by incubation with 
1% Triton x-100 (Sigma-Aldrich) in PBS for 1 hour at 65οC to cause cells lysis. 
Fluorescence of cell lysates was measured using a SynergyMx microplate reader 
(excitation: 495 nm; emission: 521 nm; BioTek; Gen5TM data analysis software).  
In the efflux assay, cells were first incubated with 500 ng/mL of FAM-Aβ1-42 for 
15 minutes (first incubation), in presence or absence of 2.5% hrecTTR. After 
incubation, the media were replaced with fresh media, and cells were further incubated 
at 37οC for a different time periods (5, 10, 15, 20 and 30 minutes) to allow efflux of 
FAM-Aβ1-42 (second incubation). Then, the supernatants were collected at each time 
point and fluorescence was quantified using fluorometer, as described previously.  
13. Basolateral-to-apical permeability assay 
For BBB transport experiments, hCMEC/D3 cells were seeded on type I 
collagen pre-coated transwells filters (polyester 12 well, pore size 0.4 µm; Costar). 
Culture medium was changed every 3 days and assays were performed 10 days after 
seeding.  
To identify filters in which apical medium leaked into the basolateral medium, 
apical media were supplemented with 0.25 mg/mL Fluorescein isothiocyanate (FITC)-
labeled dextran (molecular mass of 70 KDa; Sigma-Aldrich) before transport studies. 
The concentration of FITC-labeled dextran was determined fluorometrically (excitation: 
492 nm; emission: 518 nm) in the collected basolateral media using the same 
microplate reader as described previously. Wells, in which the basolateral FITC-labeled 
dextran concentration exceeded 125 ng/mL, indicating that the cell layer had been 
disrupted, were excluded from analysis. The FITC-labeled dextran concentration was 
calculated from a standard curve ranging from 0.25 mg/mL to 62.5 ng/mL. 
Thus, transport studies were initiated by treatment of hCMEC/D3 monolayers 
with different Aβ1-42 preparations added to the basolateral chamber of the Transwell. 
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Thus, in the basolateral compartment (Brain side) was added 0% FBS medium with 
500pg/mL Aβ1-42 supplemented or not with TTR (by addition of 2.5% human sera or 
2.5% TTR depleted serum, respectively). The apical compartment (Blood Side) was 
filled with 0% FBS medium enriched with 2.5% human sera or 2.5% TTR depleted 
serum. Experiments were also performed using cells incubated only with human serum 
or TTR depleted serum in apical and basolateral sides, in order to evaluate the 
passage of TTR across hCMEC/D3 cells in absence of Aβ1-42. Then, filters were 
incubated at 37οC, and after 3, 24 and 48 hours samples were drawn from both sides 
and were replaced with the same amount of 0% FBS medium.   
At the end of experiment, Aβ1-42 levels, in both compartments, were quantified 
by a commercially available kit as described above and following manufacture’s 
recommendations. The percentages of passage of Aβ1-42 to the blood side in 
presence or absence of TTR were calculated using the next equation: 
% passage of Aβ1 − 42 to blood side =
Concentration of Aβ1−42 Blood side
Concentration of Aβ1−42 lood side+ Concentration of Aβ1−42 brain side
 × 100  (1) 
On the other hand, TTR levels, in both sides of transwells, were measured by 
ELISA as described below. The percentage of TTR that moved on to the opposite side 
to that on which it was initially placed was calculated using the following expressions:  
% passage of TTR to blood side =
Concentration of TTR Blood side
Concentration of TTR blood side+ Concentration TTR brain side
 × 100 (2) 
% passage of TTR to brain side =
Concentration of TTR Brain side
Concentration of TTR blood side+ Concentration TTR brain side
 × 100  (3) 
14. Human TTR ELISA 
Sandwich ELISA was used to determine the TTR concentration in apical side 
and basolateral side of transwells in BBB transport studies. 96-well-plates (Maxisorp-
Nunc) were coated overnight at 4οC with a polyclonal rabbit anti-human TTR antibody 
(1:200 dilution) in 50 mM carbonate/bicarbonate buffer. After washing with PBS-T, 96-
wells were blocked with a commercial blocking reagent, PowerBlock (Biogenex), for 2 
hours at RT, and after this, samples and standards were applied to the wells during 2 
hours at RT. Then, 96-Wells were incubated, 1 hour at RT, with a sheep anti-human 
TTR antibody (1:2500; Abcam) followed by incubation with anti-sheep IgG alkaline 
phosphatase antibody produced in donkey (3:10000; Sigma-Aldrich) for 1 hour at RT. 
Development was performed with SigmaFASTTM p-nitrophenyl phosphate (Sigma-
Aldrich). The TTR concentration was calculated from a standard curve ranging from 
1.79 to 86 ng/ml. 
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15. Transmission Electron Microscopy 
hCMEC/D3 cells were grown to confluence on rat tail collagen type I coated 
transwells filters. After BBB transport experiment, cells on filters were fixed with 2% 
glutaraldehyde and 4% Paraformaldehyde (PFA) buffered in 0.1 M sodium cacodylate 
(pH 7.2). Cells were then washed repeatedly with 0.1 M cacodylate buffer, and post 
fixed overnight with 2% osmium in cacodylate buffer at 4οC. Then, washed specimens 
were dehydrated in graded ethanol solutions and embedded in epon (Electron 
Microscopy Science). The ultrathin sections were mounted on 400-mesh copper or 
nickel grids (Electron Microscopy Science). The Copper grids were used for 
ultrastructure visualization of hCMEC/D3 cells while the nickel grids were used for 
immunolabeling, as described next.   
For immuno staining, nickel grids were incubated 1 hour at RT with 14.4 % 
sodium metaperiodate followed by blocking with 2% BSA in Tris-buffered-saline (TBS) 
for 30 minutes. Then, the ultrathin sections were incubated, overnight at 4 οC, with a 
monoclonal anti-β-Amyloid antibody produced in mouse (1:200, Sigma-Aldrich). After 
washing with 0.1% BSA in TBS,  grids were incubated 1 hour at RT with immunogold 
conjugate anti-mouse IgG produced in goat (1:20, British-Biocell International).  
Finally, copper and nickel grids were double negatively stained with 2% 
uranyl acetate in ethanol and lead citrate. All grids were exhaustively observed on a 
JEOL JEM-1400 transmission electron microscope equipped with an Orious Sc1000 
digital camera.  
16. Brain Aβ efflux – In vivo preliminary study 
Aβ1-42 clearance from the brain was studied in vivo in mice with different TTR 
genotypes (n=3 for each genotype), using the intracranial microinjection technique. In 
brief, immediately before surgery mice were weighed and anesthetized with 
intraperitoneal injection of an anesthetic combination of ketamine and medetomidine 
(7.5 mg/Kg and 0.1 mg/Kg, respectively) and placed in a stereotaxic apparatus 
(Stoelting Co.). The cranium was exposed using an incision in the skin and one hole 
was drilled through the cranium over the right lateral ventricle injection site to the 
following coordinates: mediolateral -1.0 mm, anterior-posterior -0.22 mm and dorsal-
ventral -1.88 mm. Then, 2 µg of FAM-Aβ1-42 in PBS were injected into the brain using 
a 10 µL microsyringe (Hamilton Co.) connected to 26 gauge needle (RN Needle 6 pK, 
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Hamilton Co.) at a rate of 0.75 µL/min (4 µL final volume). After injection, the 
microsyringe was left in place for 3 minutes to minimize any backflow, and then, the 
incision was closed with sutures (Surgicryl), and the wound was cleaned with 70% 
ethanol.  After surgery, the animals were kept warm, using a warming pad, and blood 
samples were collected by the tail vein, periodically in a capillary tube (previously 
coated with EDTA) at 15 and 30 minutes. At the time of sacrifice (after 30 minutes), the 
mice were re-anesthetized with 75 mg/Kg ketamine and 1 mg/Kg medetomidine, and, 
after total absence of reflexes in the paw and tail, mice were perfused through the 
injection of sterile PBS pH 7.4 via the inferior vena cava until the liver becomes 
blanched. Then, liver and brain were rapidly collected, and the blood samples were 
centrifuged at 1000 rpm for 15 minutes at RT. Plasma, brain and liver samples were 
frozen at -80 οC until used.  
At the end of intracranial injection in all mice, liver and half of brain were 
weighted and homogenized in 750 µL of 50 mM TBS pH 7.4 containing protease 
inhibitor cocktail. After this, brain and liver homogenates were centrifuged for 20 
minutes at 14000 rpm at 4οC. Following centrifugation, supernatants were collected 
and then, fluorescence of brain and liver supernatants was measured using fluorometer 
(excitation: 495 nm; emission: 521 nm). Aβ1-42 levels in brain, plasma and liver 
samples were also quantified using human Aβ1-42 ELISA Kit (Invitrogen) as previously 
mentioned.  
17. Statistical analysis 
All quantitative data were expressed as mean±SEM. First of all, data was 
assessed whether it followed a Gaussian distribution. When found to follow Gaussian 
distribution, differences among conditions or groups were analyzed by one-way 
ANOVA with a Bonferroni’s Multiple Comparison Test. In the cases of non-Gaussian 
distribution, differences among conditions were analyzed by non-parametric Kruskal-
Wallis test and comparisons between two groups were made by Student t-test with a 
Mann Whitney test. p values lower than 0.05 were considered statistically significant. 
Statistically analysis were carried out using Graphpad Prism 5 software for windows. 
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Results – chapter I 
A very recent work in our laboratory, using an AD/TTR mice colony, showed 
that Aβ1-42 levels were increased in plasma of AD/TTR+/- 7 month old female mice, 
compared with plasma of AD/TTR+/+ (Ribeiro et al. , 2014). These results suggested 
that TTR has a fundamental role in sequestration of Aβ followed by its clearance from 
the periphery, thus preventing or slowing the progression of the disease.  
1. Effect of TTR in plasma Aβ levels  
In this sense, and to obtain a better knowledge on the effect of the TTR in 
plasma Aβ levels, our approach consisted in extend the study, thus evaluating plasma 
Aβ1-42 and Aβ1-40 levels in AD/TTR female mice 3-, 6- and 10- month-old with two 
different genotypes for TTR: AD/TTR+/+ and AD/TTR+/-. Aβ1-42 and Aβ1-40 levels in 
plasma were determined using sandwich ELISA. Results are shown in the form of Aβ1-
42/Aβ1-40 ratio, which was established to constitute a much more specific biomarker 
for AD, when compared to Aβ1-42 and/or Aβ1-40 levels.  
As shown in figure 14, Aβ1-42/Aβ1-40 ratio is similar between mice of the two 
genotypes studied at the age of 3 months, althought we can not speculate if these are 
already high ratios or not. This is a transgenic model with overexpression of APP and 
therefore of Aβ, and we have no comparison with a non-disease situation. Differently, 
at the age of 6 months Aβ1-42/Aβ1-40 ratio is higher for AD/TTR+/- mice than for 
AD/TTR+/+, indicating a higher degree of the disease in mice with TTR genetic 
reduction, at this age. 
It is also possible to observe that between 3 and 6 months of age, Aβ1-42/Aβ1-
40 ratio decreases for AD/TTR+/+ mice, contrarily to AD/TTR+/- animals whose 
AD/TTR+/- ratios continued to increase. We can hypothesize that AD/TTR+/+ mice tried 
to counteract the disease and Aβ accumulation by eliminating the peptides. AD/TTR+/- 
mice, however, due to their TTR reduction, are unable to prevent Aβ accumulation and 
disease progression. 
At advanced disease stages such as at 10 month of age, no differences were 
detected between AD/TTR+/+ and AD/TTR+/- animals. According to our results, Aβ1-
42/Aβ1-40 ratios were maintained in AD/TTR+/- mice (compared to 6 months), whereas 
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in AD/TTR+/+ animals, ratios were increased again, probably due to massive Aβ 
accumulation which could no longer be counteracted by TTR.  
Taken together, our results suggest that TTR influences plasma Aβ by reducing 
its levels, correlating with disease burden, i.e., Aβ1-42/Aβ1-40 ratios are elevated in 
plasma of AD/TTR+/- mice, and these animals present more signs of AD disease. 
Interestingly, statistical differences between the genotypes under study were only 
observed at 6 months, the age previously reported as the beginning of Aβ deposition in 
this model.  
  Given our results and knowing that Aβ transport is made via BBB and BCSFB, 
we decided to explore the effect of TTR in Aβ brain efflux across the BBB. 
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Figure 14 – Effect of TTR genetic reduction in plasma Aβ1-42/ Aβ1-40 ratios. Results are shown for 3-, 6- and 10-
month-old female mice with two distinct genotypes for TTR: AD/TTR
+/+
 (white bars) and AD/TTR
+/- 
(black bars). Total 
number of animals analyzed: by age, n=6 per group and by genotype, n=6 per group. Data are expressed as 
mean±SEM. Error bars represent SEM. *p<0.05 and **p<0.01 in a one-way ANOVA with Bonferroni’s multiple 
comparison test.  
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2. Effect of TTR in Aβ efflux across the BBB – in vitro 
studies 
2.1. Characterization of the BBB model 
Currently, four immortalized human brain capillary endothelial cell lines are 
available to establish an improved human in vitro BBB model – hCMEC/ D3, human 
brain microvascular endothelial cell line (hBMEC), TY10 and BB19 (Eigenmann et al. , 
2013). Regarding these cell lines, the hCMEC/D3 cell line represents a valid and 
powerful model in constructing in vitro a BBB model, and  presents a less expensive 
and more logistically feasible alternative to primary hBMEC cells (Daniels et al. , 2013).  
Thus, the hCMEC/D3 cells were used throughout this study, and firstly we 
decided to validate the model by characterizing this cell line regarding several features 
critical to the BBB integrity and structure, as well as to the Aβ efflux: expression of 
junctional proteins and expression of the main Aβ transporter at the BBB, the LRP1 
receptor.  
2.1.1. Expression of junctional proteins 
In the context of endothelial cell junctions, hCMEC/D3 cells were tested to 
claudin-3 and occludin by immunofluorescence and western blot analysis. As shown in 
figures 15 and 16, hCMEC/D3 cells are positive for TJ structural proteins, claudin-3 and 
occludin. These results indicate that, the integrity, tightness and structure as well as the 
paracellular contact between endothelial cells are guaranteed by these TJ proteins. 
Along with others TJ proteins expressed by hCMEC/D3, the claudin-3 and occludin 
ensure, with high efficiency, the control of transport across the cells monolayer.  
 
 
 
 
 
 
 
 
C 
C 
 Occludin  
79 kDa 
65 kDa 
Claudin-3  
22 kDa 
Figure 15 – Western blot analysis of TJ proteins from cell lysates of hCMEC/D3 cell line. 
30µg of total protein was subjected to SDS-PAGE and western blotting for individual markers. 
hCMEC/D3 cells expressed TJ proteins claudin-3 (22 kDa) and occludin (79 kDa and 65 kDa). 
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2.1.2. Expression of LRP1 receptor   
The expression of the efflux transport receptor – LRP1 – by the hCMEC/D3 cell 
line is a key factor when validating this model both for BBB studies purposes as for Aβ 
transport research. Similar to TJ proteins, we performed immunofluorescence and 
western blot analysis to verify if LRP1 exists in the hCMEC/D3 cells. Our results show 
that LRP1 is significantly expressed in these cells, ensuring the Aβ transport through 
the cells monolayer (Figure 17).  
Faced with these results, hCMEC/D3 cell line appears particularly appropriated 
for Aβ efflux studies across the cell monolayer. Thus, next we will present and discuss 
the experiments undertaken to investigate whether or not TTR interferes with Aβ 
uptake and efflux across the BBB.  
 
Figure 16 – Immunofluorescence staining of TJ proteins in hCMEC/D3 cell line. (A) Control of hCMEC/D3 cells 
incubated with secondary antibody (anti-rabbit Alexa 488); (B) - Immunostaining of confluent hCMEC/D3 with antibody 
against claudin-3 (green); C- Immunostaining of confluent hCMEC/D3 with antibody against occludin (green). Nuclei of 
hCMEC/cells stained with DAPI (blue).  Scale bars: 25 µM 
A B 
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2.2. Influence of TTR in Aβ internalization by hCMEC/D3 cells 
To test the hypothesis of TTR participation in Aβ brain uptake, hCMEC/D3 cells 
were incubated with labelled (FAM-Aβ1-42) or non-labelled (Aβ1-42) Aβ in presence or 
absence of TTR. Then, Aβ internalization was analyzed by FACS and fluorescence 
techniques. In these in vitro experiments, we used three different TTR sources: human 
and WT mice sera and hrec TTR protein. In the cases where hrec TTR were used, we 
utilized cell media to mimic the absence of the protein, whereas for mice and human 
sera TTR, we used TTR-/- mice sera and TTR-depleted sera, respectively.  
2.2.1. Depletion of TTR from human sera 
In order to obtain human serum without TTR, serum available in the laboratory 
was subjected to a column affinity chromatography technique to remove TTR, using an 
antibody against TTR. Then, to confirm the removal of TTR from serum, we performed 
western blot analysis. Our results (Figure 18) show no TTR in human TTR-depleted 
serum (third row) compared with initial human serum TTR (first row). Furthermore, as 
shown in figure 18 we were able to recover TTR from the beads as confirmed by the 
absence of TTR in beads after elution (second row), and also by the presence of TTR 
in eluate (fourth row). 
Therefore, TTR was efficiently removed from human serum, making this serum 
a good negative control to the presence of TTR in serum form to be used in next in 
vitro experiments.  
Figure 17 – Expression of LRP1 receptor in hCMEC/D3 cell line. (A) Immunofluorescence 
analysis of LRP1 expression in hCMEC/D3 cells stained with an antibody against LRP1 (green); 
Nucleus of cells stained with DAPI (blue); Scale bar: 10µM; (B) Western blot analysis of LRP1 
expression. The band corresponds to the c-terminal subunit (85 kDa), which contains the 
transmembrane domain and cytoplasmic tail of LRP1.  
B 
85 kDa 
 LRP1 
A 
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2.2.2. Flow cytometry analysis  
 FACS results (Figure 19) reveal that, in presence of TTR FAM-Aβ1-42 uptake 
by the hCMEC/D3 cells is significantly lower than in absence of TTR. As shown in 
figure 19, cells incubated with cell media alone internalized about 90% of the FAM-
Aβ1-42 added, whereas cells incubated with hrec TTR internalized about 72% of the 
peptide. However, human TTR-depleted serum also produced lower levels of peptide 
internalization (about 66%), suggesting that serum interferes with process. 
Nevertheless, in presence of TTR serum, the internalization levels are even lower 
(30%), indicating an effect of this protein.  
Altogether, these observations indicate that TTR produces an effect in Aβ 
internalization by the hCMEC/D3 cells, although we could not clearly ascertain the role 
of this TTR in this process. 
Figure 18 – Western blot analysis of TTR depletion from human sera. TTR were 
removed from human serum using a column affinity chromatography technique, where 
beads of protein G were linked to an antibody against TTR. After TTR linking to the beads, 
serum was applied and then collected in order to obtain TTR-free serum. Finally, TTR was 
eluted and collected.1-human serum; 2- beads of protein G after TTR elution; 3- human 
TTR-depleted serum; 4- Eluted TTR; 5- hrec TTR.  
1 2 3 4 5 
TTR monomer 
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2.2.3. Fluorescence microscopy analysis  
To further confirm if TTR is or not involved in Aβ uptake by hCMEC/D3 cells, we 
performed fluorescence analysis. We used FAM-Aβ1-42 incubated with human sera or 
hrec TTR. Alternatively we utilized Aβ1-42 incubated with TTR+/+ mice sera. Both cases 
were compared to peptide incubated in the absence of TTR (human TTR-depleted 
sera, cell media and TTR-/- mice sera, respectively).  
Fluorescence results of FAM-Aβ1-42 uptake (figure 20) demonstrated that this 
peptide incubated alone in cell media is modestly internalized by the hCMEC/D3 cells 
after 3 hours of treatment (Figure 20 B). Interestingly, cells incubated with hrec TTR 
shows higher internalization of the FAM-Aβ1-42 (Figure 20 E), indicating that TTR 
promotes Aβ uptake. However, cells treated with TTR present in human sera (Figure 
20 D), although presenting higher amounts of internalized Aβ than cells incubated with 
FAM-Aβ1-42 in cell media, evidenced a similar behavior to cells incubated with human 
TTR-depleted sera (Figure 20 C), again questioning on the role of TTR in Aβ uptake by 
hCMEC/D3 cells.  
 
Figure 19 – FACS-based analysis of FAM-Aβ1-42 internalization. hCMEC/D3 cells 
were incubated with 500 ng/mL of the FAM-Aβ1-42 in presence (human sera with TTR 
and hrec TTR, white and stripped bars, respectively) and absence (human TTR-depleted 
sera, gray bar) of TTR, during 3 hours. Data are expressed as mean±SEM. *p<0.05 and 
****p<0.0001 in one-way ANOVA, with a Bonferroni’s multiple comparison test. 
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In similar assays performed with sera from TTR+/+ mice, and with sera from TTR-
/- animals to mimic the absence of the protein, we used non-labelled Aβ (Aβ1-42) and 
thus we proceeded to immunofluorescence analysis using an anti-amyloid antibody. 
A B 
C D 
E 
Figure 20 – Fluorescence analysis of the FAM-Aβ1-42 uptake by the hCMEC/D3 cells. Endothelial cells were 
incubated with 500 ng/mL of the FAM-Aβ1-42 (green), in presence (human serum TTR or hrec TTR) and absence 
(human TTR-depleted serum) of TTR, during 3 hours. (A) Control of hCMEC/D3 cells; (B) hCMEC/D3 cells incubated 
with FAM-Aβ1-42; (C) hCMEC/D3 cells incubated with FAM-Aβ1-42 and hrec TTR; (D) cells treated with FAM-Aβ1-42 
and human TTR-depleted serum; (E) cells treated with FAM-Aβ1-42 and human serum TTR; nuclei stained with DAPI 
(blue); Scale bars = 25 µM 
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As it can be seen in figure 21, internalization of Aβ1-42 occurs (Figure 21 B) 
abundantly under all situations analyzed, and no significant differences are observed in 
the presence of TTR+/+ and TTR-/- sera (Figure 21 C and D) when compared to the 
control (Figure 21 A).  
Altogether, fluorescence results show that Aβ1-42 is internalized by the 
hCMEC/D3 cells, but suggest that TTR does not exert a significant influence in Aβ1-42 
uptake after 3 hours of incubation. Nevertheless, it is necessary take in account that, 
the immunofluorescence may not be the best approach to investigate the influence of 
TTR in Aβ uptake, because it is not a quantitative technique and therefore may fail to 
detect the differences. Indeed, FACS analysis which represents a quantitative 
technique showed significant differences in Aβ internalization by hCMEC/D3 cells, 
revealing less internalization in the presence of TTR (incubation with cell media alone 
versus with hrec TTR; incubation with human sera TTR-depleted versus with human 
sera). Nevertheless, these experiments were important to show that there are no 
significant differences in behavior between FAM-Aβ1-42 and Aβ1-42. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 – Immunofluorescence analysis of the Aβ1-42 internalization by the hCMEC/D3 cells. Cells were 
incubated with 500 pg/mL of the Aβ1-42, with TTR (
-/-
) and TTR (
+/+
) mice sera. Immunostaining of cells with antibody 
against Aβ1-42 (green); (A) Control of hCMEC/D3 cells;  (B) hCMEC/D3 cells incubated with Aβ1-42; (C) cells treated 
with Aβ1-42 and with TTR (
-/-
) mice serum; (D) cells treated with Aβ1-42 and with TTR (
+/+
) mice serum; Nuclei stained 
with DAPI (blue); Scale bars = 25 µM. 
A B 
C D 
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2.3. Fluorometric analysis  
In the light of the previous results, and because we expected a positive effect of 
TTR in Aβ transport, we wonder if three hours of incubation would be too long to 
observe differences in Aβ internalization, thus we decided to test short periods of time. 
At this point, and also aiming at establishing a faster and cheaper assay, we performed 
fluorometric analysis of cell lysates and cell conditioned media of hCMEC/D3 cells. 
Using this assay we were also able to measure Aβ efflux.  
We first evaluated FAM-Aβ1-42 uptake by hCMEC/D3 cells, in the presence or 
absence of hrecTTR. Cells were incubated for 3, 5, 10, 15 and 30 minutes, and then, 
fluorescence of cell lysates was measured in a fluorometer. As shown in figure 22, 
fluorescence levels increases until 15 minutes of incubation in both conditions, and at 
this time point an appreciable difference is noted between the two conditions, indicating 
that in the presence of hrec TTR Aβ uptake is increased. However, differences are not 
statistically different, probably due to the number of replicas used.  
Interestingly, at 30 min of incubation, and in the presence of TTR, fluorescence 
levels were already lower than at 15 min, and very similar to the ones measured in the 
absence of TTR (which continued to raise from 15 to 30 minutes).This observation 
might imply that at 30 min and in the presence of TTR, FAM-Aβ1-42 is already flowing 
out of cells, whereas in the absence of TTR the peptide is still entering. Importantly, 
these experiments shed some light on our previous FACS and fluorescence 
microscopy results, since for these periods of incubation, the peptide must have 
already gone out of cells, masking the potential effect of TTR. 
In fact, these results seems to contradict the results shown in figures 19-21, 
indicating that TTR might be an important intervening in Aβ uptake by a yet unknown 
mechanism. Despite this fact, it is important to refer that the number of replicas has to 
increase, in order to obtain results with statistical significance, and in this way be able 
to demonstrate the possible role of TTR in Aβ internalization.  
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Given our evidence that after 15 minutes FAM-Aβ1-42 levels inside cells 
achieve a maximum, and after that starts to going out of the hCMEC/D3 cells, we 
decided to focus now in Aβ efflux across the hCMEC/D3, to ascertain the role of TTR in 
this process, using the same technique. 
For this, cells were firstly incubated with FAM-Aβ1-42 for 15 minutes (first 
incubation), in presence or absence of hrecTTR, and then media replaced by fresh 
media. To allow efflux of FAM-Aβ1-42 cells were further incubated during 5, 10, 15, 20 
and 30 minutes (second incubation). 
As it can be seen in figure 23, there seems to be a tendency to faster efflux in 
absence of hrec TTR, until 10 minutes of incubation. This might imply that TTR 
contributes to maintain Aβ inside cells and/or for its degradation. However, no 
statistically significant results are observed, perhaps because the low number of 
replicas. Thus, similarly to the uptake assays, it is essential to perform these studies 
with more replicas to unravel the role of TTR in Aβ uptake and efflux. 
Figure 22 –Fluorescent analysis of FAM-Aβ1-42 uptake by hCMEC/D3 cells. Cells were incubated with 
FAM-Aβ1-42 in presence (green line) or absence (black line) of hrec TTR, during 3, 5, 10, 15 and 30 minutes. 
After this, cells were lysate and fluorescence was measured in a fluorometer (excitation: 495 nm; emission: 
521 nm). Data are expressed as mean±SEM.  
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Figure 23 – Fluorescent analysis of FAM-Aβ1-42 efflux across hCMEC/D3 cells. Cells were incubated with 
FAM-Aβ1-42 in presence (green line) or absence (black line) of hrec TTR, during 15 minutes (first incubation). 
Then, new media were replaced and cells were incubated for 5, 10, 15, 20 and 30 minutes (second 
incubation). After this, supernatants were collected and fluorescence of supernatants was measured 
fluorometrically (excitation: 495 nm; emission: 521 nm). Data are expressed as mean±SEM.  
 
 
 
 
 
 
 
 
2.4. Role of TTR in hCMEC/D3 basolateral-to-apical permeability to 
Aβ1-42  
For permeability studies, hCMEC/D3 cells were seeded on transwell filter 
inserts, as shown in figure 24 A, during 10 days until reaching maximal confluence and 
permitting TJ formation. Thus, at this point, the cell monolayers should show restricted 
paracellular permeability, and its confirmation was done using FITC-labeled dextran as 
a low molecular weight paracellular diffusion marker. In this approach, FITC-labeled 
dextran 0.25 mg/ml was added to the apical chamber, and then incubated for 1 hour. 
Wells in which FITC-labeled dextran exceeded 125 ng/mL on basolateral chamber 
were considered to have the monolayer disrupted and thus were excluded from the 
experiment (an example of this test is shown in annexes section).  
After this, cells were incubated with Aβ1-42 added to the basolateral 
compartment (Brain side) in cell media without FBS supplemented or not with TTR (by 
addition of 2.5% human sera or 2.5% TTR depleted serum, respectively).The apical 
compartment (Blood Side) was filled with 0% FBS medium enriched with 2.5% human 
sera or 2.5% TTR depleted serum. Aβ peptide was also added to non-seeded filters to 
show free passage of the peptide when compared to cell seeded ones, in which Aβ is 
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transported in a specific manner using known receptors, namely LRP1. In addition, we 
can also infer on the integrity of the monolayer. At the end, Aβ peptide transported to 
the apical chamber was determined at 3, 24 and 48 hours. 
Our data (Figure 24 B) indicates that, in presence of TTR in brain side, the 
passage of Aβ1-42 to the blood side is significantly higher compared to the situation 
where TTR was added to the blood side, in all time points evaluated. However, we still 
need to evaluate Aβ permeability in total absence of TTR and in sera-free conditions, to 
further ascertain the role of TTR in Aβ transport.  
Given our evidences, we decided to investigate if TTR crosses the hCMEC/D3 
monolayer, during Aβ1-42 efflux. To assess this, we quantified TTR in the supernatants 
of the above experiment, and also evaluated TTR apical-to-basolateral and basolateral-
to-apical passage in transwells in the absence of Aβ peptide.   
As shown in figure 24 C, TTR crosses the hCMEC/D3 cell monolayers, in both 
directions: brain-to-blood and blood-to-brain. In addition, we observe that TTR transport 
is faster from brain-to-blood than blood-to-brain. On the other hand, in presence of 
Aβ1-42 the percentages of TTR that crossed the monolayer are always lower relatively 
to the conditions without Aβ1-42, for both directions, perhaps because TTR/Aβ lessens 
its availability to cross cell monolayer. At this point we can not rule out the hypothesis 
that TTR/Aβ binding affects TTR recognition by the antibody used for the ELISA 
measurements.  
Altogether, we suggest that TTR can bind to Aβ1-42 and promote its clearance 
across the BBB, maintaining the Aβ1-42 levels balanced in brain. However, it is still 
unclear if TTR crosses the BBB together with Aβ1-42, as well as if the mechanism 
involved uses the receptors already described.  
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Figure 24 – BBB transport study across the hCMEC/D3 cell monolayers. (A) hCMEC/D3 cells were grown during 10 
days on transwells filter inserts separates an apical and basolateral compartments representing the blood and brain sides, 
respectively; (B) In efflux assay, cells were treated with Aβ1-42 (on brain side) in presence (human sera TTR) or absence 
(human TTR-depleted sera) of TTR for 3, 24 and 48 hours. Two different conditions were performed: human serum TTR 
on brain side and human TTR-depleted serum on blood side (blue line) and human TTR-depleted serum on brain side and 
human serum TTR on blood side (pink line). As a control, on no seeded transwell filter insert, Aβ1-42 was placed on brain 
side (green line). (C) Bi-directional transport of TTR across the hCMEC/D3 monolayer. Cells were  incubated in absence of 
Aβ1-42, with human serum with TTR on brain side and TTR-depleted serum on blood side (gray line) and human serum 
with TTR on blood side and TTR depleted serum on brain side (black line). TTR and Aβ1-42 concentration were quantified 
by ELISA; Data are expressed as mean±SEM; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 in one-way ANOVA, with a 
Bonferroni’s multiple comparison test. 
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We next assessed the localization of Aβ1-42 in hCMEC/D3 cell monolayers, as 
well as the ultrastructure of these cells by TEM, after the transport assays. 
Visualization of structure of cells by TEM revealed intact and confluent cell monolayers, 
without cell disruption, indicating that the integrity and paracellular contact between 
cells were guaranteed (Figure 25 A). In addition, immunogold staining against Aβ1-42 
shows that, Aβ1-42 is internalized by hCMEC/D3 cells (Figure 25 B), and that vacuoles 
are the organelle where Aβ1-42 accumulates (Figure 25 C).  
 
 
 
 
 
 
 
 
 
3. Effect of TTR in brain Aβ clearance – an in vivo 
preliminary study 
In order to investigate in vivo, the effect of TTR in Aβ clearance out of the brain, 
mice with different genotypes for TTR (TTR+/+, TTR+/- and TTR-/-) were injected with 2 
µg of FAM-Aβ1-42 on the right lateral ventricle. After 30 minutes post-injection, Aβ 
levels in brain and liver were quantified using a sandwich ELISA analysis and a 
fluorometer assay, while Aβ plasma levels, at 15 and 30 minutes, were measured only 
by ELISA. 
Our data (Figure 26 A) noticeably show that, mice with one copy of TTR have 
less Aβ in the brain compared with TTR-/- mice, after 30 minutes of injection. Thus, this 
result suggests that TTR plays a role in Aβ clearance trough the brain. However, no 
significant differences, among mice with different TTR genotypes, were observed in Aβ 
plasma levels, both for 15 and 30 minutes after injection (Figure 26 B). The measuring 
of Aβ in plasma was problematical, because the volume of blood collected was very 
low, which prevented to measure Aβ in plasma in duplicates. Furthermore, it was not 
A B C 
Figure 25 – Electron microscopic analysis of hCMEC/D3 cell line after BBB transport assay. (A) Ultrastructure image 
of hCMEC/D3 cells. Black arrows represent interface between 2 different cells. Scale bar: 1µM; (B) and (C) Immunogold 
staining with an antibody against Aβ1-42. Black dots represent Aβ1-42 and red row shows a vacuole where this peptide 
has a tendency to accumulate. Scale bars = 0.5 µM and 0.2µM, respectively.  
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possible to quantify Aβ levels in livers, perhaps due to the interference of the tissue by 
its autofluorescence. In addition, it is essential refer that, data on TTR+/+ mice were not 
shown because we believe that FAM-Aβ1-42 injection failed in two of the three mice 
available for this genotype, and thus Aβ was not detected in brain, plasma and liver 
samples.  
Nevertheless, it is necessary to take in account that, the number of animals was 
low, and it is crucial to repeat this experiment with more animals, in order to verify the 
possible effect of TTR in Aβ clearance. At this moment, we can suggest that TTR 
promotes Aβ1-42 efflux across the BBB, by increasing its transport to the periphery, 
contributing to the maintenance of Aβ1-42 levels in the brain.  
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Figure 26 – Aβ1-42 clearance across the BBB. Mice with different genotypes for TTR (TTR
+/+
, TTR
+/-
 and TTR
-/-
) were 
injected with 2 µg of FAM-Aβ1-42 on right lateral ventricle, and after this, concentration of Aβ in plasma, brain and liver were 
measured by ELISA and fluorometrically (excitation: 495 nm; emission: 521 nm). (A) Concentration of Aβ in brain after 30 
minutes of injection, in TTR
+/-
 and TTR
-/-
 mice, quantified by ELISA kit (n=2 for each genotype); (B) Concentration of Aβ in 
plasma after 15 and 30 minutes of injection, in TTR
+/-
 and TTR
-/- 
mice, measured by ELISA kit (n=3 for each genotype); Data 
are expressed as mean±SEM; ****p<0.0001 in Student t-test with a Mann Whitney test. 
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Discussion – chapter I 
AD is the most prevalent form of dementia, worldwide, and its complexity makes 
this neurodegenerative disorder one of the most investigated pathologies in the last 
years. The molecular mechanisms responsible for the known pathological features are 
very controversial, and still remain unclear. Therefore, understand how this 
neurological disease really operates and expose factors or molecules that are involved 
in AD, are two crucial aspects in deciphering AD. Thus, it has been suggested an 
association between TTR and AD, and this protein has been shown to be important in 
AD protection.  
Based on previous results of our group showing that AD mice with TTR genetic 
reduction have increased levels of brain and plasma Aβ, our working hypothesis has 
been that TTR participates in Aβ clearance from the brain. 
In this view, we investigated whether TTR had any influence in Aβ plasma 
levels in samples of AD/TTR transgenic mice, and if this effect was modified with aging. 
Our results indicated that TTR influences plasma Aβ by decreasing its levels, 
supporting the idea that TTR promotes its elimination from the brain and from the 
periphery, although, unfortunately, we did not have the opportunity to measure Aβ 
levels in the CSF of the same animals. In young mice (3 months) in which signs of 
disease are still absent, no differences were detected among the two genotypes 
studied. As disease progressed, AD/TTR+/+ were able to counteract the accumulation 
of Aβ, whereas AD/TTR+/- had their Aβ plasma levels further increased. Curiously, 
these significant differences between the two genotypes analysed were observed at 6 
months, the age which was indicated as the starting of Aβ deposition in this model 
(Oliveira et al. , 2011). At advanced stages, differences faded, and Aβ amounts 
increased in AD/TTR+/+ animals, attainting levels equivalent to the AD/TTR+/- 
counterparts. It is important to refer that the degree of disease in this model is not only 
(and probably not even mostly) produced by the higher or lower TTR concentrations. 
This is a transgenic APP and PSEN model, and thus Aβ production is highly increased 
and consequently many other pathways are affected. 
Since Aβ can be transported bidirectionally across the BBB, it has been 
hypothesized that there might be a balance between CSF and plasma Aβ levels 
(Ghersi-Egea et al. , 1996). Although Aβ peptides can be eliminated via non-specific 
bulk flow of brain ISF and BCSFB, BBB clearance seems to be responsible for the 
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mostly elimination of Aβ under physiological conditions (Shibata et al. , 2000). 
Moreover, it has been proposed that Aβ generated in the brain binds to 
cholesterol/ApoE and, in this way crosses the BBB, to be further delivery in the liver 
and kidney for its degradation (Sparks, 2007). Both at the BBB and at the liver, Aβ uses 
LRP1 to enter cells and interestingly TTR is internalized in the liver by a RAP-sensitive 
receptor and thus it is possible that TTR binds Aβ and crossing the BBB together. 
In light of this, we used the hCMEC/D3 cell line as a representative model for 
the BBB to study the influence of TTR in Aβ brain-to-blood transport. 
Our FACS and fluorescence microscopy results showed lower levels of 
internalized Aβ in the presence of TTR or no differences, respectively, contrarily to our 
expectations. We further explored this issue by changing the conditions of the assay, 
mainly by decreasing the incubations time to 15 minutes and using a fluorimetric 
measurement in cell lysates, and results indicated that TTR promoted Aβ 
internalization. Thus, we believe incubations of 3 hours (as performed for FACS and 
fluorescence microscopy) resulted in Aβ internalization followed by its efflux. Yamada 
and his co-workers using TR-BBB cells, another BBB cell line model, also showed that 
Aβ is rapidly internalized through a LRP1-mediated mechanism, approximately during 
10 minutes peptides are internalized, and then its efflux begins (Yamada et al. , 2008). 
Furthermore, it is also possible that the apparent lower Aβ inside cells resulted from its 
degradation, partially favoured by TTR. Supporting this hypothesis is our observation 
that in the fluorometric assay, during the second incubation without FAM-Aβ1-42, the 
release of peptide from cells was apparently faster in the absence than in the presence 
of TTR, after 10 min. Indeed, TTR has been characterized as a metalloprotease (Liz et 
al. , 2012) and uses Aβ as substrate, in addition to ApoA-1 and NPY peptide (Liz et al. , 
2007) and proteolysis has been suggested as a mechanism underlying TTR protection 
in AD (Costa et al. , 2008a). However, we could not clearly ascertain the role of this 
TTR in these processes, and it is necessary to repeat this experiment with a higher 
number of replicas, in order to confirm the effective role of TTR, including in Aβ 
degradation.  
It also should be noted that, in presence of serum Aβ internalization levels were 
even lower relatively to serum-free conditions, revealing its interference. Serum is a 
fluid enriched by several proteins, including proteases, which can degrade Aβ peptides 
decreasing its levels, and thus reduced its availability to be internalized by the 
hCMEC/D3 cells. By contrast, serum is also composed by apoE and α2-macroglobulin, 
known as Aβ carriers, and for this reason Aβ should form a complex with apoE or/and 
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α2-macroglobulin facilitating its internalization by cells (Qiu et al. , 1999; Kang et al. , 
2000; Gylys et al. , 2003). Again, experiments with sera were performed using 
incubations of 3 hours and thus, the effect of other Aβ transport might have been 
masked, similarly to TTR effect. Thus, further experiments using all TTR sources 
available must be undertaken using appropriate incubation times. 
Our basolateral-to-apical permeability results demonstrated a significant effect 
of the TTR at increasing Aβ efflux from brain-to-blood, suggesting a crucial role of this 
protein in Aβ clearance out the brain. Regarding this, we evaluated TTR transport 
across the hCMEC/D3 cells, and our results showed that by itself this protein crossed 
the monolayer of hCMEC/D3 cells and in absence of Aβ, its transport was even higher 
from brain-to-blood. In fact, some studies even suggest the passage of CSF TTR to 
blood as a biomarker for BBB disruption (Marchi et al. , 2003). 
In this view, we believed that in AD pathogenesis, when Aβ production starts to 
increase, TTR can rescue this peptide in order to promote its elimination across the 
BBB, preventing its deposition in neuritic plaques. At this point, remains the doubt if 
TTR crosses or not BBB linked to Aβ, and if this really occurs, what is the mechanism 
by which it happens. Hereupon, two endocytic TTR-related receptors have been 
described, namely megalin (also known as LRP2), known for renal uptake of TTR, and 
an unidenfied receptor-associated protein (RAP)-sensitive receptor (Sousa et al. , 
2000; Sousa et al. , 2001). Regarding nervous system, megalin is expressed by 
several cell types, including oligodendrocytes (Wicher et al. , 2006), astrocytes (Bento-
Abreu et al. , 2008), cortical neurons (Chung et al. , 2008) and DRG neurons (Fleming 
et al. , 2009a). One hypothesis would be TTR/Aβ complex bind to megalin, and this 
receptor triggers its transport from brain-to-blood. Supporting this proposal, Bell et al. 
demonstrated that ApoJ/Aβ complex is able to bind to the LRP2, promoting 
transcytosis of this complex and subsequent brain-to-blood efflux of Aβ (Bell et al. , 
2007). These data support our initial hypothesis, however some reports suggested that 
Aβ can play a central role in mediating increased BBB permeability, and potentially 
disrupt CNS homeostasis. A study with Tg2576 AD model, with overexpression of APP 
and therefore of Aβ, demonstrated increased BBB permeability after 4 months of age, 
prior to plaque deposition and disease onset (Ujiie et al. , 2003). Another report 
detected that Aβ increases hCMEC/D3 cell paracellular permeability, maybe as a 
consequence of reduced occludin levels at cell junctions (Tai et al. , 2010). Regarding 
these reports, during our experiment with 48 hours of incubation, Aβ could affect 
permeability of cells monolayer, allowing a higher passage of Aβ and TTR.  
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Despite our findings, these experiments were made with a BBB cell line, which 
although displaying excellent characteristics such as transporters, metabolizing 
enzymes and TJ proteins, is not enough to ascertain with reliability the role of TTR in 
Aβ efflux. It is possible ameliorate the transwell transport system by increasing barrier 
tightness. It has been reported that co-culturing of hCMEC/D3 cells with human 
astrocyte cell lines improves transendothelial electrical resistance (TEER) values, an 
indicator of paracellular permeability (Hatherell et al. , 2011). Nevertheless, in future 
reported that attempt to improve the model and at the same time we will assess the 
effect of other TTR sources, namely hrec TTR and mouse rec TTR. In addition, we will 
reduce the incubation times, since it has been reported that in vivo Aβ is effluxed from 
the brain in 30 minutes (Shibata et al. , 2000), although other works concerning Aβ 
transport using transwells have using long incubation times, similarly to our 
experiments (Nazer et al. , 2008).     
 Finally, our in vitro results were corroborated by our preliminary in vivo study, 
which demonstrated that, 30 minutes after Aβ injection, brain Aβ levels of TTR-/- mice 
were higher than in TTR+/- mice, indicating that TTR enhances Aβ elimination out of the 
brain, supporting our initial theory.  
On the other hand, we could not quantify Aβ in the liver, 30 minutes post-
injection, and also due to the small volume of plasma, we could not accurately assess 
whether or not the peptide was transported out of the brain or simply degraded. 
Moreover, this in vivo study has to be repeated with more animals per group and also 
with the three genotypes for TTR, in order to elucidate the contribution of TTR in Aβ 
efflux, and its possible implication in AD pathogenesis.  
In summary, our study showed differences in plasma Aβ levels of AD/TTR mice 
suggesting that TTR is implicated in Aβ brain efflux. Using different approaches, 
including uptake/efflux assays as well as permeability studies across a monolayer of 
cells mimicking the BBB, we showed that TTR promotes Aβ internalization by and 
transport across cerebral microvascular endothelial cells, highlighting the role of TTR 
as a transporter protein, a role that has long been known for TTR. 
We thus propose that TTR exerts its protective function in AD by binding Aβ 
peptide and delivering the peptide at the BBB for elimination, avoiding its accumulation 
in the brain and deposition in senile plaques. Future work should address the exact 
mechanism underlying TTR/Aβ interaction at the BBB, the association of Aβ 
degradation as well as the receptors involved. 
  
 
 
 
 
Chapter II: Investigating stimulus triggering 
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Material and Methods – chapter II 
1. Cell culture 
Human neuroblastoma cell line (SH-SY5Y cell line) were cultured in 25-cm2 
flasks and maintained at 37οC in a 95% humidified atmosphere and 5% CO2. Cells 
were grown in Eagle’s minimum essential medium (EMEM) and Ham’s F12 medium 
(1:1; Gibco) supplemented with 10% FBS (Gibco), 1% non-essential amino-acids 
(NEAA) (Sigma-Aldrich), 2 mM L-Glutamine (Gibco) and 1% of penicillin-streptomycin 
(Lonza). Cell culture medium was changed every 3 days.  
SH-SY5Y cells stably transfected with the plasmid carrying the human APP 
Swedish mutation K595N/M596L (isoform 695) cDNA (APPswe), were previously 
prepared (Rita costa, PhD thesis) and were available in the laboratory. The plasmid 
had been kindly provided by the Professor Sam Sisodia. This transfected cells were 
grown in 25-cm2 flasks in the same medium that SH-SY5Y cells but supplemented with 
1 mg/ml G418 (Amresco). In the next sections, the APPswe transfected SH-SY5Y cell 
line will be referred to as SH-SY5Y/APPswe cell line. During experiments all the cell 
lines were maintained in 1% FBS medium. 
2. Preparation and production of Aβ1-42 species 
The Aβ1-42 peptide was prepared as described in the chapter I. Three Aβ1-42 
species were produced: soluble, oligomers and fibers. Soluble Aβ1-42 was obtained by 
instantly diluting the peptide in the appropriate medium, whereas to prepare oligomers, 
Aβ1-42 was diluted to 100 µM in Ham’s F12 medium and incubated for 48 hours at 
4οC. For fibril formation, Aβ1-42 100 µM in Ham’s F12 medium was incubated at 37οC 
for 10 days. Samples were then visualized by transmission electron microscopy to 
confirm the presence of the different Aβ1-42 species. 
3. Transmission electron microscopy 
For visualization by TEM, sample aliquots were absorbed to carbon-coated 
collodion film supported on 400-mesh copper grids, and negatively stained with 1% 
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uranyl acetate. The grids were visualized with a JEOL JEM-1400 transmission electron 
microscope equipped with an Orious Sc1000 digital camera.  
4. Effect of Aβ species in expression of human APP and TTR 
genes 
This experiment was performed using SH-SY5Y cells grown in 25-cm2 flasks to 
90% of confluence. Then, cells were incubated for 24 hours at 37οC with 2.5 ng/mL 
Aβ1-42 and with 10 µM of each Aβ1-42 species obtained as described above (soluble, 
oligomers and fibers). Additionally, SH-SY5Y and SH-SY5Y/APPswe cells were 
incubated with 0% FBS media during 24 hours. At the end of treatment period, cells 
were harvested and RNA was extracted for RT-PCR analyses, as mentioned below.  
5. Influence of TTR in expression of human APP gene 
SH-SY5Y cells were cultured in 25-cm2 flasks until 90% of confluence. After 
culturing, cells were incubated with 1 µM hrecTTR for 24 hours at 37οC, and then RNA 
was extracted and subjected to real-time PCR (RT-PCR), as described below in gene 
expression analysis topic.  
6. Gene expression analysis 
For RT-PCR analysis, total RNA was isolated from confluent cells using Trizol 
reagent (Invitrogen) following the instructions of the manufacturers and was quantified 
by reading the absorbance at 260 nm with a NanoDrop photometer. RNA purity was 
determined using the A260/A280 ratio (average >1.8). Then, 5 µg of RNA was first-
reversed transcribed into cDNA using SuperScript R First-Strand kit (Invitrogen). The 
cDNA was then used for RT-PCR, to observe the expression of human APP (total APP 
and APP isoforms) and WT TTR genes. Human β-actin was used as an internal control 
for normalization. PCR amplification was performed using a commercial KAPA HiFi 
PCR kit (KAPAbiosystems), according to the manufacture’s protocol. The PCR primers 
and the conditions used for PCR are shown in table 2. 
Samples were further analysed on a 1% (Total APP and Human β-actin) and 
3% agarose gel (WT TTR and APP isoforms) and visualized by gel imaging system 
(ChemiDoc, Bio-Rad) in the presence of ethidium bromide.  
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Table  2.  List of PCR primers sequences and PCR conditions. 
Gene Primer sequences PCR conditions 
β-Actin 
Reverse: 5’ CAC CAT CAG GCC CTG GTC CC 3’ 
Forward: 5’ ACA GAG CCT CGC CTT TGC CG 3’ 
Initial denaturation: 95
ο
C, 5 
minutes 
Denaturation, annealing and 
extension (35 cycles): 
95
ο
C, 45 seconds 
55
ο
C, 1 minute 
72
ο
C, 1.30 minutes 
Final extension: 72
ο
C, 5 minutes 
WT TTR 
Sense: 5’ ATG GCT TCT CAT GGT CTG CT 3’ 
Anti-sense: 5’ GAA GTC CCT CAT TCC TTG GG 3’ 
Total 
APP 
Reverse: 5’ TCT GTG GTG GTG GTG GTG 3’ 
Forward: 5’ GAT GCG GAG GAG GAT GAC 3’ 
APP 
isoforms 
Reverse: 5’ CTG GAA ATG GGC ATG 3’ 
Forward: 5’ GTA GTA GAA GTA GCA G 3’ 
Initial denaturation: 95
ο
C, 5 
minutes 
Denaturation, annealing and 
extension (35 cycles): 
95
ο
C, 45 seconds 
45
ο
C, 45 seconds 
72
ο
C, 1.30 minutes 
Final extension: 72
ο
C, 5 minutes 
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Results – chapter II 
It has been reported that TTR levels in CSF are reduced in several AD patients, 
but the meaning of this decrease is still not clear (Serot et al. , 1997; Gloeckner et al. , 
2008; Hansson et al. , 2009). In the last years, it has been proposed that TTR 
sequesters Aβ in CSF, but other sites of sequestration were not been identified. Further 
it was assumed that, in CNS, TTR was only produced in choroid plexus and not in 
neurons (Li et al. , 2011a). However, Li and co-workers demonstrated that neurons 
transcribe TTR mRNA, which is subsequently translated to produce TTR protein. They 
also suggested the possibility of  the CSF TTR concentration being determined in part 
by its synthesis in neurons, and that reduced TTR levels are associated with neuronal 
loss (Li et al. , 2011b). In addition, an in vitro study showed that TTR is expressed in 
SH-SY5Y neuroblastoma cell line, and that it is up-regulated by the AICD fragment of 
APP, specifically derived from the APP695 isoform (Kerridge et al. , 2014). This group 
also showed that, accumulation of functional AICD caused TTR up-regulation and 
subsequent a decrease of Aβ levels. Furthermore, other group demonstrated in SH-
SY5Y cells, primary hippocampal neurons and the hippocampus of APP23 mice, that 
TTR expression is significantly improved by HSF1 (Wang et al. , 2014). Thus, one can 
propose that, TTR protects through sequestration of Aβ in neuritic plaques and 
consequently its reduction by clearance out of the brain.  
In light of these discoveries, we decided to investigate if certain stimulus, 
namely different Aβ species (soluble, oligomers and fibers), can induce TTR gene 
expression and alteration in APP isoforms gene profile using SH-SY5Y cell line. 
Additionally, we also evaluated if the overexpression of the 695APPswe isoform affects 
TTR expression versus the influence of TTR in APP gene expression.  
1. Effect of Aβ species in the expression of TTR and human 
APP genes 
1.1. Influence of soluble Aβ1-42 in TTR and APP genes expression  
The SH-SY5Y cell line does not express TTR and to explore the potential effect 
of Aβ species in induction of the TTR gene expression and also in the alteration of APP 
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gene expression (including total APP gene and APP isoforms), SH-SY5Y cells were 
incubated firstly with a physiological concentration (500 pg/ml) of soluble Aβ1-42.  
Analysis by RT-PCR showed no TTR expression (data not shown) and even 
after using Aβ1-42 at 2.5 ng/ml, no TTR was observed (Figure 27).  
Since it has been reported that, in AD, there is a shift in the expression of APP 
isoforms with APP-KPI isoforms being more expressed, we decided to investigate if 
Aβ1-42 could induce such alteration. However, we did not detect any variation in total 
APP and APP isoforms expression in the presence or absence of the peptide (Aβ 2.5 
ng/ml). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2. Effect of Aβ aggregated forms in TTR and APP isoforms genes 
expression 
Since Aβ peptide induces toxicity in oligomerized and aggregated forms, we 
next evaluated TTR and APP isoforms gene expression in SH-SY5Y cells incubated 
Figure 27 – RT-PCR analysis of TTR and APP genes expression in SH-SY5Y cell line after 
treatment with Aβ1-42.  SH-SY5Y cells were incubated with 2.5 ng/mL of Aβ1-42 (+) and without this 
peptide (-) in 0% FBS media, during 24 hours. Total RNA was extracted and subjected to RT-PCR, 
using primers for APP isoforms (APP 770 (504 bp), APP 751 (437 bp) and APP 695 (269 bp)), Total 
APP (245 bp), WT TTR (452 bp) and β-Actin (190 bp). Plasmid which expresses TTR was used as a 
control (ctrl).   
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with 10 µM of soluble Aβ, oligomers and fibers,  for 24 hours. The presence of different 
Aβ species was confirmed by ultrastructure by TEM (Figure 28). The use of synthetic 
Aβ1-42 is highly challenging and achieving a preparation containing 100% of soluble 
monomeric peptide is nearly impossible. Thus, visualization of the soluble Aβ 
preparations revealed mostly individual particles but also some small aggregates 
(Figure 28 A, arrows and arrowheads, respectively); quite different, the oligomeric 
preparations were abundantly populated by aggregates and oligomers of different sizes 
(Figure 28 B); also very distinct from the above samples, the fibril preparations, 
although heterogenous in nature,  presented as main species fibrillar structures with 
the characteristic diameter of amyloid fibrils (approximately 10 nm wide) (Figure 28 C, 
D). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RT-PCR results (Figure 29) reveal that, the presence of Aβ oligomers and fibers 
induces TTR expression in SH-SY5Y cells, and also causes an increase in the 
expression of all APP isoforms.  
Figure 28 – Morphological characterization of Aβ species by TEM analysis. (A) Soluble Aβ1-42 (obtained by 
instantly diluting the peptide in the appropriate medium); (B) Oligomers (Aβ1-42 was diluted to 100 µM in Ham’s F12 
medium and incubated for 48 hours at 4οC); (C) and (D) Fibrils (100 µM Aβ1-42 in Ham’s F12 medium was incubated 
at 37οC for 10 days); Scale bars: A, B and C – 200 nm; D – 100 nm.  
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1.3. TTR expression in APPswe transfected cells 
Finally, we assessed TTR gene expression in cells overexpressing the human 
APPswe gene to further investigate the mechanisms leading to the presence of TTR in 
neuronal cells and also in an attempt to confirm the results obtained with exogenous 
aggregated Aβ. However, we do not observe any TTR expression, similarly to non-
transfected cells (Figure 30). It is possible that the levels of peptide secreted by 
transfected cells were not sufficient to induce TTR gene expression or that secreted Aβ 
was not in the form of oligomers and/or aggregates. 
 
 
 
 
 
 
Figure 30 – RT-PCR analysis of TTR gene expression in SH-SY5Y cells transfected with APPswe 
gene. SH-SY5Y (SH1 and SH2) and SH-SY5Y/APPswe (SHswe1 and SHswe2) cells were incubated 
with 0% FBS media during 24 hours and RNA were extracted and subjected to RT-PCR, using WT TTR 
primer (452 bp). 
Figure 29 – RT-PCR analysis of TTR and APP genes expression in SH-SY5Y cells, after treatment with different 
forms of Aβ1-42. Cells were incubated with 10 µM of soluble Aβ (Aβ1 and Aβ2), oligomers (olig1 and olig2) and fibers 
(Fib1 and Fib2), and as control (Ctrl1 and Ctrl2), cells were incubated only with 0% FBS media, during 24 hours. Total 
RNA was extracted and subjected to RT-PCR, using primers for APP isoforms (APP 770 (504 bp), APP 751 (437 bp) 
and APP 695 (269 bp)), WT TTR (452 bp) and β-Actin (190 bp). Plasmid which expresses TTR was used as a control 
(TTR ctrl).   
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Taken together, these findings suggest that the presence of neurotoxic species 
of Aβ, such as oligomers and fibers, induces neuronal TTR mRNA expression and 
might result in TTR protein neuronal synthesis, which in turn binds to oligomers and 
fibers of Aβ. Consequently, this interaction will interfere with Aβ oligomerization and 
fibrillization by disrupting oligomers and fibril, and will result in increased Aβ clearance, 
preventing the toxic damage in neurons.  
 
2. Influence of TTR in expression of human APP gene 
As already mentioned, brains from AD and non-AD subjects present different 
patterns of APP isoforms expression, suggesting that some of them contribute to 
disease development. 
We next evaluated if the presence of TTR induces changes in such profile. As 
depicted in figure 31, no differences are observed in cells incubated with or without 
TTR, suggesting that the mechanism of TTR protection in AD does not affect APP 
expression. 
 
 
Figure 31 – RT-PCR analysis of TTR and APP genes expression. SH-SY5Y cells were incubated with 1 µM 
hrecTTR (SH+TTR1 and SH+TTR2), and as control (SH1 and SH2), cells were incubated only with 0% FBS 
media, during 24 hours. Total RNA was extracted and subjected to RT-PCR, using primers for APP isoforms 
(APP 770 (504 bp), APP 751 (437 bp) and APP 695 (269 bp)), and β-Actin (190 bp). 
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Discussion – chapter II 
AD is characterized as an inevitably progressing dementia. In susceptible brain 
regions, such as the hippocampus and cortex, there is an accumulation of Aβ peptides 
into extracellular neuritic plaques. Previous studies have shown an important function 
of TTR as an Aβ carrier suggesting that TTR binds and rescues the peptide in the CSF 
(Schwarzman et al. , 1994; Schwarzman et al. , 1996). In fact, Aβ clearance 
mechanisms are becoming an important aspect in the prevention of AD pathology, 
since it is now believed that in AD sporadic cases, accounting for the larger majority of 
AD cases, Aβ clearance is impaired, contrarily to older believes which considered Aβ 
production to be increased. 
TTR is predominantly synthesized by the liver where more than 90% of the 
protein is produced. The remaining is produced by the choroid plexus and the retina, 
but other sites of synthesis have been described in mammals (Oliveira et al. , 2011). 
For a long time, investigators supposed that the locally secreted TTR protein acted as 
a carrier of thyroid hormones between blood and brain, seeing that the BBB is not 
permeable to these molecules. TTR production within the CNS was ascertained by 
immunochemical techniques demonstrating the participation of organelles involved in 
the CSF secretory pathway (Aleshire et al. , 1983). Herbert and colleagues showed in 
1986 that TTR, within the CNS, is solely synthesized by the choroid plexus, suggesting 
a special role for TTR in the brain or CSF, also speculating if this function differs or not 
from its established plasma transport functions (Herbert et al. , 1986). However, recent 
reports raised controversy on this issue describing TTR synthesis in other areas of the 
brain, namely in the hippocampus. Stein and Johnson described that the lack of 
degeneration in Tg2576 mice, was associated with increased level of TTR in the 
hippocampus (Stein et al. , 2002), and other group demonstrated that neurons 
transcribe TTR mRNA, which is subsequently translated to produce TTR protein (Li et 
al. , 2011b). Moreover, intraneuronal TTR was seen in the brains of normal humans 
and mice and in AD patients and APP23 AD transgenic mice. The APP23 brains 
showed co-localization of extracellular TTR with Aβ in plaques (Buxbaum et al. , 2008). 
Very recently, some suggestions on TTR neuronal synthesis have emerged and 
Kerridge et al. showed that TTR is expressed in SH-SY5Y cell line, and that it is up-
regulated by the AICD fragment of APP, which derived from the APP695 isoform 
(Kerridge et al. , 2014). The accumulation of functional AICD resulted in TTR up-
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regulation and Aβ decreased levels. Wang and colleagues verified that TTR expression 
is enhanced by HSF1 in SH-SY5Y cells, primary hippocampal neurons and the 
hippocampus of APP23 mice (Wang et al., 2014). Nevertheless, the mechanism of 
neuronal TTR induction, both in biological and pathological conditions is far from being 
unraveled and in this view, this study has focused in the investigation of certain 
stimulus, such as the different Aβ species (soluble, oligomers and fibers), at inducting 
TTR gene expression and at altering the profile of APP isoforms gene expression, 
using a human SH-SY5Y neuroblastoma cell line. In addition, it was evaluated also if 
SH-SY5Y cells over-expressing 695APPswe were relevant to induction TTR gene 
versus the influence of exogenous TTR in APP gene expression.  
Analysis by RT-PCR revealed no TTR expression after treatment with soluble 
Aβ, both at low and high concentrations. On the other hand, Aβ1-42 oligomers and 
fibrils, the neurotoxic elements in AD, induced neuronal TTR expression. This finding 
suggests that TTR can be produced in neurons under certain conditions. Thus, when 
neuronal cells are in need, TTR is synthesized and then bind to oligomeric and fibrillar 
forms of Aβ, promoting their clearance at the BBB (as evaluated in chapter I) to prevent 
neurotoxicity. As previously described, in vitro, TTR is able to inhibit and to disrupt Aβ 
fibrils (Costa et al. , 2008b). Furthermore, as described in several studies, TTR has 
protease activity and cleaves Aβ producing fragments non-toxic or less toxic than the 
full-length peptide (Liz et al. , 2004; Costa et al. , 2008a). Thus, it is possible that TTR 
acts in several ways aiming at protecting against AD.  Our results contradict other 
studies, which reported that TTR mRNA levels are significantly increased in SH-SY5Y 
cells over expressing 695APPswe (Li et al. , 2010; Kerridge et al. , 2014). Furthermore, 
Li and co-workers showed that increased TTR mRNA and protein in cultured 
hippocampal neurons from AD model mice and also demonstrated an increase in TTR-
stained neurons in human AD brains, suggested that neuronal TTR transcription might 
be substantially induced by Aβ or its precursors (Li et al. , 2011b). Others reported that, 
sAPPα or sAPPβ leads to increased expression of protective genes, such as TTR, to 
confer neuroprotection (Stein et al. , 2004; Li et al. , 2010). Indeed, transfected cells, 
due to the presence of the human APPswe gene, should generate large amounts of Aβ 
peptide compared to the non-transfected cells, and our results might indicate that either 
1) Aβ did not reach a concentration high enough, or 2) the peptide is not sufficiently 
aggregated, to induce TTR expression.  
The APP gene is alternatively spliced to produce three major isoforms including 
APP695, APP751 and APP770. APP695 is predominantly expressed in neurons and 
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lacks the KPI domain, contrarily to APP751 and APP770 which contain this domain 
(Matsui et al. , 2007). Studies show that both protein and mRNA levels of KPI-
containing APP isoforms are elevated in AD brains and are associated with increased 
Aβ deposition  (Menendez-Gonzalez et al. , 2005). In light of this, we investigated if Aβ 
could induce such alteration in total APP and APP isoforms. With regard to soluble Aβ 
no significant variation was observed. By contrast, Aβ oligomeric and fibril forms 
caused an increase in APP gene expression as deduced by increase observed for all 
APP isoforms analysed, suggesting a mechanism of positive feedback while disease 
develops: when Aβ starts to aggregate and accumulate in brain, the APP transcription 
is signalized and then, more Aβ is produced, contributing to plaque formation in the 
brain and disease progression.  
We also evaluated if, on the contrary, TTR as a protective molecule could 
decrease APP expression, namely the KPI-containing isoforms. However, we found no 
differences in SH-SY5Y cells incubated with or without human recTTR, suggesting that 
TTR protection in AD is mostly associated with Aβ binding and clearance but not with 
Aβ precursor. 
In summary, our results demonstrated that TTR gene expression is induced by 
aggregated and fibrillar Aβ forms suggesting that neuronal synthesis of this protein 
might be a natural protective response to the cellular challenge presented by Aβ 
aggregation. Thus, protection appears to be a function of increased TTR production 
with binding of Aβ aggregates and fibrils Aβ and consequently reduction of their toxicity 
by elimination and/or degradation.  
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This study highlights the importance of TTR as protective protein in AD trough 
the maintenance of Aβ levels in brain by its elimination across the BBB and/or its 
degradation. 
Based on different approaches used, we can assume that TTR promotes Aβ 
efflux through the BBB, preventing its accumulation in the brain and deposition in 
extraneuronal plaques and in this way reduces Aβ-associated toxicity. In the future, it 
would be interesting to address the precise mechanism underlying TTR/Aβ interaction 
at the BBB, namely by testing the participation of LRP1 and P-gp, by blocking these 
molecules with specific antibodies or through the use of interference RNA; it will be 
important to assess TTR binding these molecules, directly or via Aβ, for instance by co-
immunoprecipitation approaches. Given that TTR has proteolytic activity proposed to 
be relevant in the CNS, the studies should not just focus on Aβ transport but also on its 
degradation, for instance by performing TCA precipitation of labelled Aβ after the 
transport assays. In future experiments, the importance of TTR stability in AD and in 
particular in its assistance in Aβ transport across the BBB, should also be explored. For 
that, the permeability studies in the transwell system can be performed in the presence 
of TTR stabilizers, such as IDIF. 
Our study presented for the first time evidence that neuronal TTR expression 
can also be induced by Aβ oligomers and fibrils, indicating that neuronal synthesis of 
TTR can be a natural mechanism to protect neurons against Aβ toxicity. It will be 
important to unravel the mechanism behind TTR neuronal synthesis, by confirming our 
findings in vivo. It is also important to understand how our data relates to other reports 
on the regulation of TTR expression in the brain. 
In summary, TTR role in the CNS might encompass, among other effects, 
assistance in Aβ brain efflux at the BBB. Under a pathological situation, such as AD, 
and in the presence of threshold of Aβ toxic species, TTR neuronal synthesis is 
induced to confer protection by binding to Aβ aggregates and fibrils and consequently 
by reducing their toxicity (for instance, by elimination across the BBB and/or 
degradation).  
Finally, because Aβ is also transported across the BCSFB and since TTR is the 
major Aβ binding protein in the CSF, it is fundamental to research on the effect of TTR 
in Aβ efflux at the BCSFB. For that we propose to use primary cultures of choroid 
plexus epithelial cells and also in vivo studies.  
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Annex I – Evaluation of integrity of hCMEC/D3 cells monolayer 
During basolateral-to-apical experiment, the tightness and integrity of the BBB 
cells monolayer, was monitored by the permeability of FITC-labeled dextran across the 
monolayers, as previously described in material and methods section, in chapter I.  
An example of integrity and permeability assay is demonstrated in table 3. As it 
can be seen, the transwell 6 was excluded from the study, because the concentration 
of FITC-dextran in basolateral side exceeded 125 ng/mL, suggesting that cell 
monolayer was disrupted, leaving FITC-dextran molecules pass freely. The remaining 
transwells presented less than 125 ng/mL of FITC-dextran in basolateral side after 1 
hour of incubation. Thus, these monolayers were well organized and cell-cell 
interactions were formed, preventing free passage of FITC-dextran across the cells, 
and therefore, transwells were used in hCMEC/D3 basolateral-to-apical permeability to 
Aβ.  
 
Table 3 – Evaluation of integrity of hCMEC/D3 cells monolayer in transwells filters. 
 
 
 
 
 
Transwells 
Concentration of 
FITC-dextran in 
basolateral side 
(ng/mL) 
1 12.2 
2 -13.3 
3 -17.8 
4 36.8 
5 20.3 
6 499.1 
7 -18.07 
8 -18.9 
